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Publiekssamenvatting
Staat van Infectieziekten in Nederland,  
2013 
De uitbraak van mazelen in 2013 was de meest in het 
oog springende infectieziekte van dat jaar. Dit blijkt 
uit de Staat van Infectieziekten in Nederland 2013, die 
inzicht geeft in ontwikkelingen van infectieziekten bij 
de Nederlandse bevolking. Daarnaast worden de 
ontwikkelingen in het buitenland beschreven die voor 
Nederland relevant zijn. Met deze jaarlijkse uitgave 
informeert het RIVM beleidsmakers van het ministerie 
van Volksgezondheid, Welzijn en Sport (VWS).
Elk jaar komt in de Staat van Infectieziekten een 
thema aan bod; dit jaar is dat de hoeveelheid jaren 
in goede gezondheid die verloren gaan (ziektelast) 
door infectieziekten. Sommige infectieziekten, zoals 
maag-darminfecties, komen erg vaak voor maar 
veroorzaken over het algemeen geen ernstige 
klachten. Andere daarentegen, bijvoorbeeld tetanus, 
komen slechts zelden voor maar veroorzaken relatief 
veel sterfgevallen. Een gezondheidsmaat die deze 
aspecten van ziekten combineert is de Disability 
Adjusted Life Year (DALY). 
Voor 32 infectieziekten is de ziektelast in Nederland 
tussen 2007 en 2011 geschat. De gemiddelde jaarlijkse 
ziektelast voor de totale Nederlandse bevolking was 
het hoogst voor ernstige pneumokokkenziekte (9444 
DALY’s per jaar) en griep (8670 DALY’s per jaar), die 
respectievelijk 16 en 15 procent van de totale 
ziektelast van alle 32 infectieziekten 
vertegenwoordigen. Na polio en difterie (0 gevallen in 
de onderzochte periode), werd de laagste ziektelast 
geschat voor rodehond op 0,14 DALY’s per jaar. De 
ziektelast voor deze ziekten is zo laag dankzij het 
Rijksvaccinatieprogramma. De ziektelast per individu 
varieerde van 0,2 DALY’s per honderd infecties voor 
giardiasis (diarree die wordt veroorzaakt door een 
parasiet), tot 5081 en 3581 DALY’s per honderd 
infecties voor respectievelijk hondsdolheid en een 
variant van de ziekte van Creutzfeldt-Jakob. 
Voor alle ziektelaststudies geldt dat de resultaten 
afhankelijk zijn van de modelparameters en 
aannames, en van de beschikbaarheid van accurate 
gegevens over de mate waarin de ziekten 
voorkomen. Toch kunnen deze schattingen 
informatief zijn voor beleidsmakers binnen de 
gezondheidszorg om prioriteiten te kunnen 
aanbrengen in preventieve en andere maatregelen.
Trefwoorden: Staat van infectieziekten, infectieziekten, 
ziektelast, DALY, meldingsplichtige infectieziekten
Abstract
State of Infectious Diseases in the Netherlands, 
2013
The measles outbreak in 2013 was the most striking 
infectious disease of that year. This is demonstrated 
in the State of Infectious Diseases in the Netherlands 
2013, which provides insight into infectious disease 
trends in the Dutch population. Developments in 
other countries that are relevant for the Netherlands 
are also described. This annual RIVM publication 
informs policy-makers from the Ministry of Health, 
Welfare and Sport (VWS). 
Every year the State of Infectious Diseases publishes 
reports on a particular theme. This year’s topic 
concerns the estimation of disease burden: how 
many years of healthy life are lost due to infectious 
diseases? Some infectious diseases, such as 
gastrointestinal infections, occur frequently in the 
population, but do not generally give rise to serious 
complaints. In contrast, other diseases, for example 
tetanus, occur rarely but may lead to a high risk of 
death. A summary measure of population health 
that combines the morbidity and premature 
mortality attributable to a disease in a single 
quantity is the Disability Adjusted Life Year (DALY). 
For 32 infectious diseases, we estimated the disease 
burden in the Netherlands between 2007 and2011. 
The highest average annual burden for the total 
Netherlands population was estimated for invasive 
pneumococcal disease (9444 DALYs per year) and 
influenza (8670 DALYs per year), which represented 
16 and 15 percent, respectively, of the total burden of 
all 32 diseases considered. After poliomyelitis and 
diphtheria (no cases in the period investigated), the 
lowest burden was estimated for rubella, at 0.14 
DALYs per year. The extremely low burden for these 
diseases is due to the National Immunisation 
Programme. The disease burden per individual 
varied from 0.2 DALYs per 100 infections for 
giardiasis (diarrhea that is caused by a parasite), to 
5081 and 3581 DALYs per 100 infections for rabies 
and variant Creutzfeldt-Jakob disease, respectively. 
As with all burden of disease studies, results depend 
on disease model parameters and assumptions, and 
on the availability of accurate data on the incidence 
of infection. Nevertheless, estimates of disease 
burden can be informative for public health policy-
makers regarding the prioritisation of preventive and 
other measures.
Keywords: state of infectious diseases, infectious 
diseases, disease burden, DALY, notifiable diseases
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1
Introduction
This is the ninth edition of the report on State of 
Infectious Diseases in the Netherlands. This annual 
publication is written to inform policy makers at the 
Ministry of Health, Welfare and Sports (VWS) and at 
the Centre of Infectious Diseases at RIVM.
This State of Infectious Diseases in the Netherlands 
starts with a chapter on the main national and 
international infectious diseases events that occur-
red in the Netherlands in 2013. This chapter includes 
the table with annual numbers of notified diseases 
in the Netherlands.  
One particular topic is highlighted each year. This 
year the focus is on the burden of infectious disease 
in the Netherlands. In this report, we present the 
first comprehensive national burden of disease 
estimates, for 32 infectious diseases in the period 
2007-2011. We computed the disability-adjusted life 
years (DALY) measure, which combines the burden 
due to both morbidity and premature mortality 
associated with all short and long-term consequen-
ces of infection. The highest average annual burden 
was observed for invasive pneumococcal disease 
(9444 DALYs/year) and influenza (8670 DALYs/year), 
which represents 16% and 15%, of the total burden 
of all 32 diseases considered, respectively. Results 
depend on disease model parameters and assumpti-
ons, and on the availability of accurate data on the 
incidence of infection, which usually must be 
estimated using imperfect surveillance data. 
Estimates of disease burden van be informative for 
public health policy decisions regarding the prioriti-
sation of interventions and preventive measures.
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2
The state of 
Infectious 
Diseases in the 
Netherlands, 2013
2.1 Introduction
In this chapter, we provide an overview of key 
infectious diseases events in 2013 previously 
reported in the weekly reports written by the Dutch 
early warning committee (http://signaleringsoverleg.
infectieziekten.eu/). These include both national and 
international events. Table 2.1 shows the number of 
notifications of all notifiable infectious diseases in 
the Netherlands by year of disease onset in the 
period 2006-2013. In section 2.2 to 2.5 we describe 
the most important events concerning mandatory 
notifiable diseases under the Dutch Public Health Act 
(1). Section 2.6 deals with notable occurrences 
regarding non-notifiable infectious diseases for the 
Netherlands, including events in the rest of the 
world. We have included information from the year 
2014, in case an outbreak or unusual event started in 
2013 and continued into 2014. We have not included 
information about outbreaks or events that started 
in 2014. 
2.2 Group A-diseases
Polio 
In 2013, 416 patients with poliomyelitis were reported 
to the World Health Organization (WHO) globally 
(www.polioeradication.org). This number is higher 
than in 2012 with 223 reported cases, but an enor-
mous decrease since 1998 (350.000 cases), the year 
the World Health Assembly resolved to eradicate the 
disease. Of the 416 patient in 2013, 160 (38 %) were 
reported from the last 3 countries were poliomyelitis 
is endemic (Nigeria 53 patients, Pakistan 93 patients, 
and Afghanistan 14 patients). The other patients were 
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Table 2.1 Number of notifications of notifiable infectious diseases in the Netherlands by year of disease 
onset, 2006-20131.
Group* Infectious disease 2006 2007 2008 2009 2010 2011 2012 2013
Group A
 
Smallpox 0 0 0 0 0 0 0 0
Polio 0 0 0 0 0 0 0 0
Severe Acute Respiratory 
Syndrome (SARS)
0 0 0 0 0 0 0 0
Middle East Respiratory 
Syndrome (MERS)
0b
Viral haemorrhagic fever 0 0 1 0 0 0 0 0
Group B1
 
 
Human infection with zoonotic 
influenza virus
0a 0 0 0 0 0
Diphtheria 0 0 0 0 0 1 1 0
Plague 0 0 0 0 0 0 0 0
Rabies 0 1 0 0 0 0 0 1
Tuberculosis 1030 999 1013 1158 1068 1004 957 848
Group B2
 
 
 
 
 
 
 
 
Typhoid fever 20 25 27 27 24 20 17 25
Cholera 3 3 5 4 0 3 3 0
Hepatitis A 276 161 185 180 261 116 124 109
Hepatitis B Acute 244 224 225 215 196 155 174 140
Hepatitis B Chronic 1499 1570 1591 1772 1570 1544 1322 1127
Hepatitis C Acute 25 41 28 39 30 72 53 64
Pertussis 4381 7743 8135 6350 3691 7044 13859 3474
Measles 1 10 109 15 15 51 19 2650
Paratyphi A 20 11 9 17 19 14 25 22
Paratyphi B 14 21 26 16 16 27 18 15
Paratyphi C 0 2 1 3 0 1 3 2
Rubella 5 1 2 7 0 3 1 57
STEC/enterohemorragic E.coli 
infection
42 111 154 279 397 647 903 844
Shigellosis 242 406 438 413 533 584 750 469
Invasive group A streptococcal 
disease
28a 255 211 186 178 201
Clusters of foodborne 
infection**
95 97 85 39 48 42 47 34
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Table 2.1 (continued) Number of notifications of notifiable infectious diseases in the Netherlands by year of 
disease onset, 2006-20131.
Group* Infectious disease 2006 2007 2008 2009 2010 2011 2012 2013
Group C
 
 
 
 
 
 
 
 
 
 
Anthrax 0 0 0 0 0 0 0 0
Mumps 7a 80 563 609 397 204
Botulism 1 1 7 0 0 0 2 0
Brucellosis 7 6 5 3 6 1 3 5
Creutzfeldt-Jakob disease 22 15 15 20 27 27 28 23
Creutzfeldt-Jakob disease - 
Variant
0 0 1 0 0 0 0 0
Yellow fever 0 0 0 0 0 0 0 0
Invasive Haemophilus influenzae 
type b infection
0a 16 31 20 22 18
Hantavirus infection 2a 7 19 7 23 4
Legionellosis 440 325 339 256 473 315 308 306
Leptospirosis 27 42 29 22 29 29 44 27
Listeriosis 8a 56 69 86 70 74
Malaria 241 229 221 234 245 242 199 164
Meningococcal disease 177 184 155 158 143 99 106 108
MRSA-infection (clusters 
outside hospitals)
4a 16 13 6 2 10
Invasive pneumococcal disease 
(in children age 5 years or 
younger)
5a 42 57 48 53 28
Psittacosis 67 53 79 81 73 70 44 53
Q fever 13 195 1003 2424 411 77 63 20
Tetanus 0a 1 2 5 2 1
Trichinosis 0 0 1 1 0 1 0 0
West Nile virus infection 0a 0 1 1 0 0
1 Up until the year 2012, the allocation of a case to a specific year was based on the date of notification to the public health  authori-
ties. From 2012 onwards the allocation of a case to a specific year has been based on the date of disease onset or, if unknown, the 
date of diagnosis or, if unknown, the date of notification. As a result, the numbers presented in this table, differ from the numbers 
presented for the same years in tables from previous ‘State of Infectious Diseases’ reports. The Table was sourced from the Dutch 
notifiable infectious diseases database ‘Osiris’ on April 29 2014. The number of reported cases is subject to change as cases may be 
entered at a later date or retracted upon further investigation. The longer the time between the period of interest and the date this 
Table was sourced, the more likely it is that the data are complete and the less likely they are to change. 
* Notifiable infectious diseases in the Netherlands are grouped depending on the legal measures that may be imposed 
** Number of clusters, not number of cases
a  not notifiable until 1 December 2008, so the number for 2008 is for one month only
b not notifiable until 3 July  2013.
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reported from Cameroon (4), Syrian Arab Republic 
(35), Ethiopia (9), Somalia (194) and Kenya (5). 
In addition, since February 2013, wild polio virus type 
1 has been detected in sewage samples from 
different sampling sites in southern and central 
Israel. In addition, positive environmental samples 
have also been collected from the West Bank and 
Gaza. These findings indicate widespread wild polio 
virus circulation in this region without identified 
clinical cases. As Israel is a popular destination for 
European Union travellers and vice versa, there is a 
risk of import cases of polio and outbreaks (particu-
larly within groups with a low vaccination coverage) 
in European countries (http://www.ecdc.europa.eu/
en/publications/Publications/Communicable-
disease-threats-report-21-sep-2013.pdf).
In addition, since October 2013 cases due to wild 
poliovirus type 1 were confirmed in the Syrian Arab 
Republic. Cases were from different parts of the 
country, indicating  widespread circulation of the 
virus. Wild poliovirus was last reported in Syria in 
1999. Most of the cases were very young (below two 
years of age), and were unvaccinated or partly 
vaccinated due to the war situation in the country. 
WHO estimated that immunisation rates in the Syrian 
Arab Republic declined from 91% in 2010 to 68% in 
2012. With the arrival of many refugees from Syria 
into the Netherlands, there is a small risk of importa-
tion of poliovirus. Although the Dutch population is 
generally well protected against polio, introduction of 
poliovirus in the Dutch orthodox protestant commu-
nity could result in an epidemic. In the Netherlands, 
the last poliomyelitis epidemic occurred in 1992-1993 
when 71 polio patients were notified who were 
unvaccinated because of religious beliefs (2).
In May 2014 the WHO declared polio a public health 
emergency of international concern. The WHO 
Director-General determined that the spread of wild 
poliovirus to 3 countries – during what is normally 
the low-transmission season – was an ‘extraordinary 
event’ and a public health risk to other countries, 
and that a coordinated international response was 
essential to prevent exacerbation during the 
high-transmission season (http://www.who.int/
mediacentre/news/statements/2014/polio-
20140505/en/). Currently 10 countries have active 
wild poliovirus outbreaks that could spread to other 
countries through the movement of people. From 
January to April 2014 – that is the low-transmission 
season for polio – the virus was transmitted to 3 
countries: in central Asia (from Pakistan to 
Afghanistan), in the Middle East (from Syrian Arab 
Republic to Iraq) and in Central Africa (from 
Cameroon to Equatorial Guinea). 
MERS-coronavirus
In September 2012, a new coronavirus was identified 
post-mortem from a patient suffering from acute 
pneumonia and subsequent renal failure in the 
Kingdom of Saudi Arabia (3). Internationally this 
novel virus has since been named Middle East 
Respiratory Syndrome-coronavirus (MERS-CoV). 
From September 2012 to May 9 2014, WHO had been 
informed of a total of 536 laboratory-confirmed 
cases of infection with MERS-CoV, including 145 
deaths, globally (http://www.who.int/csr/disease/
coronavirus_infections/MERS_CoV_Update_09_
May_2014.pdf?ua=1). All cases have been directly or 
indirectly linked, through travel or residency, to 4 
countries in the Middle East: Saudi Arabia, Qatar, 
Jordan, and the United Arab Emirates. This includes 
cases reported from Germany, the United Kingdom, 
France, Italy and Tunisia. In May 2014 2 Dutch 
patients were diagnosed with MERS-CoV infection. 
These patients had visited Saudi Arabia (4).   
There has been person-to-person transmission on a 
small scale amongst people who had close contact 
with cases, for example by sharing a household or 
work place, or by caring for a patient in a health care 
setting. Coronaviruses belong to a large family of 
viruses causing a range of illnesses in humans, from 
the common cold to severe acute respiratory 
syndrome (SARS). Coronaviruses also cause a range 
of diseases in animals. Research found a high 
prevalence of antibodies against MERS-CoV in 
camels from different countries, suggesting that 
these animals are a potential reservoir (5, 6). A role 
for bats as reservoir has also been suggested (7). 
2.3 Group B1-diseases
Tuberculosis
In 2013, there were 848 notifications of tuberculosis 
in the Netherlands, of which 469 were of pulmonary 
tuberculosis (http://www.rivm.nl/dsresource?objecti
d=rivmp:241606&type=org&disposition=inline). Of 
the pulmonary tuberculosis patients, 141 had smear 
positive tuberculosis, the most infectious type of 
tuberculosis. The number of notified tuberculosis 
patients has decreased since 2002 and the decrease 
continued into 2013. The incidence rate in 2013 was 
5.1 per 100,000 inhabitants. Nearly three quarters 
(74%) of tuberculosis diagnoses in 2013 originated 
from people born abroad. Of these patients, the 
largest group (24%) was born in Somalia. In 2013, 
there were 17 notifications of multidrug-resistant 
(MDR)-tuberculosis cases. There have not been any 
notifications of cases with extreme drug-resistant 
(XDR)-tuberculosis since 2009, in which year 3 cases 
State of Infectious Diseases in the Netherlands, 2013  |  13
were notified. In 2012, the percentage of patients 
who successfully completed their treatment was on 
average 85%.
Rabies
In 2013, a Dutch citizen died from rabies. He had 
been bitten by a dog on a compound in Port-au-
Prince, Haiti on 6 May 2013 (http://www.promed-
mail.org/direct.php?id=1791201). He had not been 
vaccinated against rabies before the incident. On 20 
June 2013, after his return to the Netherlands, he was 
admitted to a hospital, with suspected rabies. 
Presence of rabies virus (genotype 1) was confirmed 
in skin biopsies of the neck, in liquor and saliva. In 
the Netherlands, 4 people have been notified with 
this disease: in 1962, 1996, 2008 and in 2013. 
Human infection with zoonotic influenza virus
On 31 March 2013, Chinese authorities reported the 
identification of a novel reassortant influenza A/
H7N9 virus isolated from 3 unlinked fatal human 
cases of severe respiratory disease in eastern China, 
2 in Shanghai and 1 in Anhui province. This was the 
first time human infections with avian influenza 
virus A/H7N9 have been identified (8). This event 
marked the identification of fatal human infections 
caused by a low pathogenicity virus of avian origin. 
Since then, human cases have continued to be 
reported from China. As of 18 February 2014, there 
were 354 laboratory-confirmed cases of A/H7N9 
reported in China (with a case–fatality rate of 32%). 
In addition, the virus has been detected in 1 asymp-
tomatic case in Beijing. Since the beginning of 2014, 
there has been a notable increase in the number of 
human cases, which may indicate a growing wild or 
domestic bird reservoir, an increase in the number of 
exposed individuals, enhanced transmissibility of 
the virus, a seasonal transmission pattern or a 
combination of these factors. The continued and 
increasing transmission of a novel reassortant avian 
influenza virus capable of causing severe disease in 
humans in one of the most densely populated areas 
in the world remains a cause for concern due to the 
pandemic potential. However, the most likely 
current scenario for China is that these outbreaks 
remain zoonotic in which the virus is transmitted 
sporadically to humans in close contact with the 
animal reservoir, similar to the influenza A/H5N1 
situation. Influenza A/H5N1 has been circulating in 
poultry in China for almost two decades, causing 
occasional human cases (654 globally, of which 46 
cases in China). In early 2014, a case most probably 
infected in Beijing was detected by and reported 
from Canada. Three human cases of influenza A/
H10N8 virus have been reported in Jiangxi province 
in China (9). The first human case was reported by 
the Chinese authorities on 17 December 2013, in a 
73-year-old female with multiple underlying medical 
conditions, who was admitted to hospital on 30 
November 2013, and died on 6 December 2013. 
According to local authorities, the patient had visited 
a local live-poultry market. Since then 2 more cases 
have been detected, of which 1 has died. In May 
2013, a human case of influenza A/H6N1 was 
detected in Taiwan (10). While likely human-to-
human transmission of A/H7N9 and A/H5N1 in 
clusters of reported cases has been documented in a 
few instances, there is no indication of sustained 
human-to-human transmission.
2.4 Group B2-diseases 
Hepatitis A
From January 2013, 1,444 cases of hepatitis A virus 
(HAV) infection have been reported by 12 European 
countries as potentially linked to the same ongoing 
HAV infection outbreak (http://ecdc.europa.eu/en/
publications/Publications/ROA-Hepatitis%20A%20
virus-Italy%20Ireland%20Netherlands%20
Norway%20France%20Germany%20Sweden%20
United%20Kingdom%20-%20final.pdf). Although 
the outbreak was first associated with travellers to 
Italy, 8 other countries (France, Germany, Ireland, 
Norway, the Netherlands, Sweden, United Kingdom 
and Finland) have reported cases with no travel 
history in the 2 months before the onset of their 
disease. In the Netherlands, 15 cases have been 
reported with the outbreak strain. Epidemiological 
investigations and trace back activities in different 
countries did not pin point a clear hot spot, but 
suggested frozen berries as the vehicle of a common, 
continuous source in Europe. However, other 
hypotheses such as cross contamination in a food 
production environment or that the outbreak strain 
was already widespread but had gone undetected, 
cannot be excluded. The current outbreak in several 
European countries poses a risk of secondary 
transmission through infected individuals. 
Measles
In 2013, a large measles outbreak occurred in the 
Dutch orthodox protestant community in the 
Netherlands. The outbreak started in May 2013 and 
continued on until February 2014 (11). The first 2 
measles cases in this outbreak were reported from 
an orthodox Protestant school in the Province of 
South Holland on 27 May 2013. As of 26 February 
2014, there were 2,640 reported cases, including 182 
hospitalisations and 1 death. Most cases were 
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orthodox Protestants (91%) and unvaccinated (95%). 
Cases who acquired infection in the Netherlands 
have been reported by 24 Municipal Health Services 
(Figures 2.1 / 2.2). The case with the earliest date of 
onset of rash in this outbreak had not travelled 
abroad and the initial source of infection remains 
unknown. 
A unique outbreak control intervention was imple-
mented: a personal invitation for measles-mumps-
rubella (MMR) vaccination was sent to parents of all 
children aged 6–14 months living in municipalities 
with an MMR vaccination coverage below 90% as 
the main risk group for developing measles compli-
cations. This age group is at relatively high risk since 
most mothers are currently vaccinated against 
measles, which leads to lower levels of maternal 
antibodies than natural infection. In addition, all 
unvaccinated individuals aged 14 months up to 19 
years were invited for catch-up vaccination through 
the media. National recommendations to reduce the 
risk of measles in healthcare workers were finalised 
in the beginning of the outbreak. These suggest that 
healthcare workers born after 1965 should actively 
check their vaccination or measles infection status 
and complete their MMR vaccination schedule if 
needed. Healthcare workers born before 1965 and 
those vaccinated twice are considered immune. All 
hospitals in the Netherlands have been approached 
and encouraged to comply with these recommenda-
tions. The effects of the control measures will be 
evaluated.
A single dose of monovalent measles vaccine was 
included in the Dutch national immunisation 
programme in 1976 for children aged 14 months. 
Since 1987, vaccination against measles, mumps and 
rubella in a two-dose schedule has been available to 
children, at 14 months and nine years of age. 
Vaccination coverage is generally high in the 
Netherlands. In 2012, the MMR coverage was 96% 
for the first dose and 93% for the second dose (birth 
cohorts 2010 and 2002, respectively). However, 
vaccination uptake is low in some specific groups, 
for religious reasons (orthodox Protestantism), 
anthroposophic reasons, and in those with a critical 
attitude towards vaccination. While the latter 2 
groups are scattered across the Netherlands, 
orthodox Protestants are a close-knit community of 
250,000 persons, mostly living in an area that 
stretches from the south-west to the north-east of 
the country, the so-called Bible belt. Vaccination 
coverage in general among orthodox Protestants 
was assessed in 2006-2008 to be about 60%. 
Rubella
In May 2013 a rubella outbreak occurred at an 
orthodox Protestant school in the province of South 
Holland. In total 54 cases were reported, mainly 
children aged between 4 and 11 years. Most cases 
were unvaccinated because of religious beliefs. In 
2013 a large measles outbreak occurred in the same 
community (see Measles). Three other rubella cases 
were in adults, all whom had a link to Poland where 
a large rubella outbreak was ongoing.
2.5  Other relevant events related to 
non-notifiable infectious diseases
Tularaemia
In 2013 and 2014 4 human cases were diagnosed 
with tularaemia (see Figure 2.3). The first case of 
indigenous tularaemia in the Netherlands since 1953 
was detected in 2011 (12). In 1953 8 family members 
were infected after eating an infected hare. 
Tularaemia is a zoonotic infection caused by 
Francisella tularensis. Tularaemia naturally occurs in 
rabbits, hares and in rodents, especially voles, vole 
rats and muskrats. Transmission to humans has 
been reported by direct contact with infected 
animals, arthropod bite, inhalation of contaminated 
dust and ingestion of contaminated food or water. 
The clinical presentation depends on the mode of 
transmission. From 2011, diseased or dead hares 
presented at the Dutch Wildlife Health Centre for 
research on cause of death, are routinely tested on 
tularaemia. In 2013 en 2014 3 hares tested positive 
for tularaemia. Tularaemia is an endemic disease in 
wildlife in many European countries, including 
Belgium and Germany. 
Chikungunya in the Carribean 
On 6 December 2013, two laboratory-confirmed 
cases of chikungunya without a travel history were 
reported on the French part of the Caribbean island 
of Saint Martin, signalling the start of the first 
documented outbreak of chikungunya in the 
Americas. Between 6 December 2013 and 27 March 
2014 the virus spread to several Caribbean islands, 
including Sint-Maarten and over 17,000 suspected 
and confirmed cases were reported (13). Further 
spread and establishment of the disease in the 
Americas is likely, given the immunologically naïve 
population, the high number of people travelling 
between the affected and non-affected areas and 
the widespread occurrence of efficient vectors. 
Chikungunya is a mosquito-borne viral disease 
caused by an alphavirus from the Togaviridae family. 
The virus is transmitted by the bite of Aedes mos-
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Figure 2.1 Reported measles cases by week of onset of exanthema and Municipal Health Service region, 
the Netherlands, 1 May 2013 – 26 February 2014 (n=2,640).
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Figure 2.2 Reported measles cases by municipality, the Netherlands, 1 May 2013 – 26 February 2014 
(n=2,640).
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Figure 2.3 Geographical spread of tularaemia cases in the Netherlands, 2011-2014.
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quitoes, primarily Aedes aegypti and Aedes albopictus. 
The typical clinical signs of the disease are fever and 
severe arthralgia, which may persist for weeks, 
months or years after the acute phase of the 
infection. General complications include myocardi-
tis, hepatitis, ocular and neurological disorders. The 
detection and diagnosis of the disease can be 
challenging especially in settings where dengue is 
endemic, because the similarities in symptoms 
between the diseases. 
Up to the year 2005, Chikungunya was endemic in 
parts of Africa, Southeast Asia and on the Indian 
subcontinent only. From 2005 to 2006, large 
chikungunya outbreaks were reported from 
Comoros, Mauritius, Mayotte, Réunion and various 
Indian states. Autochthonous transmission in 
continental Europe was first reported from Emilia-
Romagna, Italy, in August 2007 with more than 200 
confirmed cases and subsequently in France in 2010 
with 2 confirmed cases (14, 15). In both areas the 
vector Aedes albopictus has been established. In 2014 
Chikungunya became a notifiable disease in the 
Dutch Carribean. 
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3
Disease burden of 
infectious diseases 
in the Netherlands
Key points
• The first comprehensive national burden of 
disease estimates, for 32 infectious diseases in 
the period 2007-2011, are presented for the 
Netherlands.
• The disability-adjusted life years (DALY) 
measure was computed, which combines the 
burden due to both morbidity and premature 
mortality associated with all short and 
long-term consequences of infection.
• The highest average annual burden is 
observed for invasive pneumococcal disease 
(9444 DALYs/year) and influenza (8670 DALYs/
year), which represents 16% and 15% of the 
total burden of all 32 diseases, respectively. 
• Results depend on disease model parameters 
and assumptions, and on the availability of 
accurate data on the incidence of infection, 
which is usually estimated using imperfect 
surveillance data.
• For public health policy decisions regarding 
the prioritisation of interventions and preven-
tive measures, estimates of disease burden 
can be informative.
3.1 Introduction
Accurate estimates of the current and future burden 
of specific infectious diseases, and information 
regarding the ranked estimated burden among a 
number of infectious diseases, can support national 
public health policy and priority setting within the 
field of infectious disease epidemiology. Infectious 
diseases and their short- and long-term consequen-
ces (i.e., complications, sequelae) are quite hetero-
geneous in terms of severity and the risk of morta-
lity. Infections with certain pathogens are common 
but with relatively mild health consequences, 
whereas others may be associated with a high 
mortality rate, but occur only rarely. Consequently, it 
is difficult to compare the burden of different 
diseases based solely on incidence or mortality rates. 
To enable such comparisons, a number of composite 
measures of health have been developed that 
combine morbidity and mortality (1).
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In particular, the burden of disease methodology, as 
developed jointly by the World Bank, Harvard School of 
Public Health, and the World Health Organization 
(WHO) for the Global Burden of Diseases, Injuries, and 
Risk Factors study (GBD), is a suitable approach as it 
facilitates setting priorities among infectious diseases 
and comparing their relative disease burden (2-4). 
Commissioned by the WHO, Murray and Lopez 
performed a first study of the global burden of disease 
(4), in which they estimated the global disease burden 
for a wide range of diseases, including mental illness, 
chronic conditions, (consequences of) accidents, and 
infectious diseases. To compare the impact of these 
diseases in terms of quality of life and their effect on 
life expectancy, they developed a composite measure: 
the disability-adjusted life year (DALY) (see section 
3.2.1). The idea behind this approach is that the impact 
of a particular disease can be divided into the number 
of years of life lost (i.e., premature mortality) and the 
number of years lived at less than full health (i.e., 
morbidity). The result is a single measurement unit that 
quantifies the years of healthy life lost due to a certain 
disease or infection. The DALY has since been widely 
applied for estimating disease burden at national, 
regional, and global levels (4-8).
In practice, the DALY computation is not as straightfor-
ward as desired. The relevant data are not always 
available, and a number of often critical choices and 
assumptions need to be made (9). Symptomatic as 
well as asymptomatic infections may lead to long-
term chronic sequelae, which may not always be 
recognised as being originally caused by an infection. 
For many infectious diseases the possible relationships 
with later chronic sequelae are not clearly established 
or quantified. Therefore, criteria are needed to decide 
if the strength of evidence is sufficient for attributing 
(part of the) disease burden of those sequelae to an 
infectious cause, an essential requirement for the GBD 
2010 project (10). Attributing long-term sequelae to 
infection with a specific pathogen may also require 
adding disease burden that occurs over long time 
periods (e.g., the time between acute hepatitis B 
infection and death may span decades) (9).
 
Our adopted methodology is consistent with the 
methodology developed for a pilot study in which the 
burden was estimated for seven infectious diseases 
in 23 European countries (11) and for a preliminary 
report of the estimated infectious disease burden 
within the Netherlands (12). In the current report, the 
first comprehensive burden estimates for 32 infecti-
ous diseases in the Dutch context are presented. This 
set of diseases comprises infectious diseases that are 
currently responsible for, or are able to cause, 
significant burden. In the coming years, we intend to 
further develop and refine the methods and aim to 
produce annual estimates.
3.2 Methodology
Several fundamental methodological decisions are 
required for burden of disease estimation. We 
decided to take the pathogen as a starting point (in 
contrast to an outcome-based approach), and to 
work with incidence data (see section 3.2.1.3). The 
preference for the latter was to use, if available, 
statutory notification data to which a correction 
factor is applied to account for the under-reporting 
and under-ascertainment inherent in notification 
data (see section 3.2.1.4 and Appendix 2). For 
non-notifiable diseases, we located the best 
alternative data source(s) to determine incidence; for 
instance, from laboratory surveillance and sentinel 
general practice /primary health care surveillance 
systems (see Appendix 1). 
Outcome trees, which describe the various health 
outcomes and how they are related within a disease’s 
natural history, transition probabilities between health 
outcomes, disability weights and durations, and 
various other parameters, assumptions and decisions 
were adopted from the expert-reviewed disease 
models developed as part of the Burden of 
Communicable Diseases in Europe (BCoDE) project and 
disease models developed by Havelaar et al. (13) (see 
online appendix www.rivm.nl/bibliotheek/rapporten/
appendix150205001.pdf and sections 3.2.1.5-3.2.1.7). 
The following sections describe the computation of 
the disability-adjusted life year (DALY) measure, the 
choices, assumptions, and parameters that are 
required when calculating disease burden, and which 
aspects of these assumptions are important for 
infectious diseases in particular.
3.2.1 DALY
The DALY is the simple sum of two components: 
1.  premature mortality, quantified as the number of 
years of life lost (Years of Life Lost = YLL), and
2.  morbidity, the number of years lived with that health 
outcome (Years Lived with Disability = YLD). The 
DALY for a pathogen is therefore the sum of the YLL 
and YLD associated with all health outcomes 
specified within the natural history of infection by 
that pathogen.
DALY = YLL + YLD
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3.2.1.1 YLL
Premature mortality associated with a health 
outcome is expressed in terms of the number of 
years of life lost (YLL). YLL is calculated as the 
number of deaths (di) multiplied by the remaining 
life expectancy (ei) at the age of death, summed over 
all n fatal health outcomes of the disease, in a given 
population and time period. Typically, di is estimated 
from the case-fatality rate associated with a particu-
lar health outcome. The remaining life expectancy, ei, 
is age- and sex-specific (see Table 3.1), and case-
fatality rates can also be specified as dependent on 
age and/or sex.
n
YLL =  di x ei
 i=1
3.2.1.2  YLD
YLD is calculated for each health outcome by 
multiplying the number of incident cases (Ii) by the 
disability weight (DWi) - a measure of the severity of 
the health outcome/disabling condition - and by the 
duration (Di) of the health outcome. For example, if a 
health outcome has a disability weight of 0.25, this 
implies that a year living with this condition is similar 
to 75% of the value of a healthy life-year (or the loss 
of a quarter of a year due to ill health). All parame-
ters can be specified by age and/or sex. The YLD for 
a disease is the sum of the YLD associated with all n 
health outcomes comprising the natural history for 
that disease, in a given population and time period.
  n
YLD =  li x DWi  x Di
   i=1
3.2.1.3 Pathogen-based / incidence-based 
approach
We adopted the pathogen as the starting point for the 
disease burden calculation. This is opposed to the 
approach where one starts with a certain health 
outcome, such as cancer, and then assigns the 
burden of specific cancers to pathogens and other 
causes. When the pathogen is taken as a starting 
point, the focus of burden calculation is on all health 
outcomes that can be causally attributed to that 
specific pathogen. These outcomes may include 
various categories of disease; for example, health 
outcomes associated with Salmonella spp. infection 
include diarrhoea, Irritable Bowel Syndrome (IBS), 
and reactive arthritis. This approach gives justice to 
the potential long-term sequelae of infectious 
diseases, and permits a better understanding of the 
health benefits associated with the prevention of 
infections. The main disadvantage of the pathogen-
based approach is a greater risk of double counting, 
with consequent over-estimation of the total disease 
burden.
As opposed to working with prevalence data, we 
calculate burden based on incidence data. In this way, 
all new cases of a particular disease are counted, and 
the burden associated with all health outcomes 
(including those that might occur in future years) 
that are attributable to the initial infection is 
included, and is assigned to the year of initial 
infection. Working with incidence data can lead to a 
better understanding of the possible future health 
gains from prevention initiatives that decrease the 
risk of transmission, and consequently reduce the 
incidence of infection. However, the incidence 
approach does not take into account the burden of 
disease among patients who have contracted a 
(chronic) infectious disease in the past, and still 
suffer from the health consequences (e.g., HIV and 
hepatitis B infection).
3.2.1.4 Under-estimation of incidence
It is important to establish whether the incidence 
data used for disease burden estimates adequately 
reflect the actual situation, or additional adjustment 
for under-ascertainment and/or under-reporting is 
needed (14, 15). Under-ascertainment refers to the 
extent to which incidence is under-estimated 
because there are cases in the community that do 
not get in contact with health services, such as their 
general practitioner. They may have no contact 
because infection is asymptomatic, or because they 
suffer from mild illness only. Under-reporting refers to 
those infected individuals who do contact health 
services, but whose disease status is incorrectly 
diagnosed or classified, or fails to be reported to the 
organisation responsible for surveillance.
Adjustment for both under-ascertainment and 
under-reporting can be done in a single step or in 
two steps, depending on the disease-specific data 
available. Appropriate multiplication factors (MFs) - 
with uncertainty intervals if available - were derived 
by disease surveillance specialists. These multiplica-
tion factors were based either on published studies 
or from analyses of relevant datasets, or on some 
combination of the two (see Appendix 2). 
Additionally, for a number of diseases (see Table 3.2), 
correction of the reported case numbers for the 
coverage of the surveillance system needed to be 
applied because the sentinel laboratory surveillance 
systems used do not cover the whole Dutch 
population.
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3.2.1.5 Life expectancy, disability weights and 
durations
Life expectancy values are required for the calcula-
tion of YLL as well as YLD (i.e., for long-term 
sequelae that persist until death). Remaining life 
expectancy for those persons who die from an 
infectious disease or its complications was derived 
from standard life tables, as the age of these 
individuals was either known or could be approxi-
mated. In the GBD study, a standard life table (West 
Level 26) was adopted, with a life expectancy at birth 
of 82 years for women and 80 years for men (2, 16). 
This life table was selected because it contains the 
highest reported national life expectancy (82 years 
for Japanese women). We have chosen to use the 
West Level 26 as well (see Table 3.1).
Table 3.1  Life expectancy (e) of males and females by age group (a) (17).
  Standard e(a)
West Level 26
Age group Males Females
0 79.94 82.43
1-4 77.77 80.28
5-9 72.89 75.47
10-14 67.91 70.51
15-19 62.93 65.55
20-24 57.95 60.63
25-29 52.99 55.72
30-34 48.04 50.83
35-39 43.10 45.96
40-44 38.20 41.13
45-49 33.38 36.36
50-54 28.66 31.68
55-59 24.07 27.10
60-64 19.65 22.64
65-69 15.54 18.32
70-74 11.87 14.24
75-79 8.81 10.59
80-84 6.34 7.56
85+ 3.54 4.25
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The YLD for a given health outcome is weighted for 
the severity of illness using disability weights. A 
disability weight can range from 0 (perfect health) to 
1 (death) and is typically based on the preferences of 
a panel that rates the relative undesirability of 
hypothetical health outcomes. These panels can 
include patients, medical experts, and lay people 
from the general population. The current research 
adopted the set of disability weights compiled for 
the BCoDE project, which were developed using a 
mix of Person-Trade-Off and more novel techniques 
(18), similar to the methods used by the GBD (4) and 
other disease burden assessments (19).
Disability durations for each health outcome, 
required for the calculation of YLD, were also 
adopted from the BCoDE project. These values were 
based on literature review and/or expert opinion.
3.2.1.6 Outcome trees
For all pathogens investigated, an ‘outcome tree’ was 
prepared in order to represent the natural history of 
disease, linking incident cases to all associated health 
outcomes, including sequelae and death. Outcome 
trees provide a structural representation of disease 
progression by ordering all relevant health outcomes 
associated with the pathogen along a time-line (see 
Figure 3.1), where the chance of developing a subse-
quent health outcome is quantified by a transition 
probability. The starting point is usually acute sympto-
matic infection (8, 9, 14). The health outcome ‘asymp-
tomatic infection’ does not contribute to the disease 
burden, but may lead to symptomatic cases or 
sequelae later in life (e.g., hepatitis B infection). 
Dividing a single health outcome into multiple ‘health 
states’ (in terms of severity) was necessary for several 
pathogens, in order to better represent the burden 
when a particular health outcome is associated with 
differing degrees of disability, and possibly leads to 
different sequelae or to death, with transition probabi-
lities that depend on severity. Pathogen outcome trees 
developed as part of the BCoDE project, which have 
been reviewed by disease specialists at the European 
Centre for Disease Prevention and Control (ECDC) and 
the National Institute for Public Health and the 
Environment (RIVM), were adopted (see online 
Appendix, www.rivm.nl/bibliotheek/rapporten/
appendix150205001.pdf). For a number of diseases, 
default BCoDE values for certain parameters were 
modified to better reflect the Dutch context (see 
online Appendix, www.rivm.nl/bibliotheek/rappor-
ten/appendix150205001.pdf).
For two of the set of 11 foodborne diseases investi-
gated, we estimated the burden for the period 
2007-2011 based on the BCoDE approach; for the 
other nine we used the disease models developed by 
Havelaar et al. (13, 20). These researchers have 
considerable experience in burden estimation for 
foodborne diseases, and apply a sophisticated 
methodology that is designed specifically for 
foodborne diseases in the Netherlands.
3.2.1.7  Other decisions
Incidence data for most pathogens were stratified by 
sex and by 5-year age-group, except for the first two 
and last age-groups (<1 years, 1-4 years, 85+ years). 
However, for most foodborne diseases (other than 
shigellosis, listeriosis, toxoplasmosis, hepatitis A 
infection, and variant Creutzfeldt-Jakob disease), six 
different age-groups were used: <1 years, 1-4 years, 5-11 
years, 12-17 years, 18-64 years and 65+ years. For 
listeriosis and hepatitis A infection, incidence was based 
on active surveillance with known age of cases. 
Congenital toxoplasmosis by definition occurs only in 
newborns (<1 year age-group), and acquired toxoplas-
mosis occurs predominantly in the age group 18–64 
years. Incidence data for most diseases were adjusted 
using pathogen-specific multiplication factors to 
account for under-estimation of the number of cases by 
notification or other surveillance sources. The incidence 
of disease due to food-related pathogens (except for 
shigellosis and variant Creutzfeldt-Jakob disease) was 
based on several national cohort studies (13), rather 
than notification data adjusted by multiplication factors. 
For details regarding statutory notification and the 
various surveillance systems involved, see Appendix 1. 
For a number of pathogens, there was sufficient 
information to specify age- and/or sex-dependent MFs. 
For others, a single MF – either a point estimate or a 
range, depending on the information available – was 
applied for both sexes and all age-groups. Multiplication 
factors were chosen to either adjust in one step 
(under-estimation), or in two steps (under-reporting 
and under-ascertainment) (see Appendix 2).
In contrast to the majority of chronic diseases, the 
incidence of a given infectious disease may fluctuate 
greatly from year to year. These fluctuations may be 
due to infection attack rates that vary across seasons 
(e.g., as observed for influenza), or because of build-up 
of a pool of susceptibles over years (e.g., measles in the 
Netherlands). As a result, the estimated disease burden 
for a given year may not be representative of the 
‘typical’ burden associated with the pathogen. As a 
partial solution to this issue, we estimated the annual 
incidence as the mean incidence over a five-year period 
(2007-2011) whenever possible. However, in the 
presence of an increasing or decreasing temporal trend, 
taking the mean incidence may lead to under- or 
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Figure 3.1 An outcome tree linking infection to all associated health outcomes. The outcome tree displays 
how individuals progress through various disease stages from acute infection through sequelae and 
death. The process is quantified by attaching probabilities to the arrows depicting transitions, and 
durations to the various health outcomes (9).
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over-estimation, respectively, of the disease burden. 
For diseases exhibiting outbreak years (e.g., measles, 
pertussis, rubella, influenza, and Q fever), we discuss 
the magnitude of the impact of an outbreak year on 
our estimates.
Because data on the transition probability parame-
ters and multiplication factors are often based on 
small samples or are limited in other ways, uncer-
tainty in these values was modelled by specifying a 
probability distribution for the uncertainty and 
employing appropriate sampling techniques (see 
section 3.2.2 below).
Finally, adjustments such as age-weighting and 
discounting (2) can be integrated within the DALY 
framework. We chose not to implement either of 
these extensions, in agreement with GBD 2010 
methods (10).
3.2.2 Software for burden estimation
For this report, we used version 0.94 of the BCoDE 
software toolkit (21) to estimate the burden for 23 
diseases (i.e. excluding campylobacteriosis, cryptospori-
diosis, giardiasis, hepatitis A infection, listeriosis, 
norovirus infection, salmonellosis, toxoplasmosis, and 
infection with STEC O157; see section 3.2.1.6). As the 
BCoDE toolkit implements the incidence- and patho-
gen-based approach (see section 3.2.1.3), all health 
outcomes including and subsequent to acute infection 
are taken into account in the burden computation. 
Uncertainty intervals around mean DALYs and other 
outputs were estimated using Monte-Carlo sampling 
methods; a total of 5000 iterations were run per disease 
model. Specifically, for multiplication factors specified 
as distributions (Uniform or PERT; the latter is a special 
case of the Beta distribution specified by three parame-
ters: a minimum, most likely, and maximum value), the 
mean and 95% uncertainty interval were computed 
from the output distribution. In case of a constant 
multiplication factor, uncertainty around the point 
estimate value (no. cases x MF) was simulated as a 
Gamma distribution with shape parameter equal to the 
point estimate, and with scale parameter set to 1 (20).
3.3   Estimated annual disease burden 
in the Netherlands, 2007-2011
The total number of reported cases per year, the 
selected multiplication factors, and the estimated 
annual incident cases and deaths over the period 
2007-2011 for all 32 diseases are provided in Table 3.2. 
Table 3.3 gives a comprehensive overview of the  
national burden estimates for each of the 32 diseases 
investigated, reporting several measures (YLD/year, 
YLL/year, DALYs/year, DALYs per 100 cases). Mean
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Table 3.2 Total number of new cases in the years 2007-2011, multiplication factors (MFs) chosen to adjust 
for under-estimation, and the estimated annual number of new cases and deaths (averaged over the period 
2007-2011 and adjusted for under-estimation), per disease.
Disease Total number of new cases MF(s) chosen 
(see Appendix 2)
Estimated annual 
number 2007-2011
2007 2008 2009 2010 2011 Infections Deaths
Sexually transmitted infections
Chlamydia (a) 35658 35658 35658 35658 35658 UR: 1.111 181481 0.002
Gonorrhoea * 1830 1969 2426 2815 3578 UE: 2.53 9195 0.03
Hepatitis B infection 227 219 208 197 159 UA: 1.33
UR: Uniform(1.20,1.22)
1124 14
Hepatitis C infection 44 45 52 47 68 UE: Uniform(1, 
5.12)*29/30 + Pert(0, 
47, 464.4)*1/30 (d)
1233 8
HIV infection (b) 1194 1246 1134 1093 855 UE: 1 1922 115
Syphilis * 660 793 711 696 545 UE: 4.21 5761 0.4
Vaccine-preventable diseases
Diphtheria 0 0 0 0 0 n.a. 0 0
Invasive 
H. influenzae infection *
115 108 129 143 139 UE: Uniform(1.05,1.20) 143 11
Invasive
meningococcal disease *
186 159 157 137 99 UE: 1.05 155 16
Invasive 
 pneumococcal disease (e)
2648 2328 2408 2252 2496 UE: Uniform(1.05,1.20) 2729 410
Measles 10 109 15 15 50 UE: 
Uniform(11.11,14.93)
518 2
Mumps * n.a. n.a. 32 424 642 UA: 1.84
UR: 1
673 0.005
Pertussis * 7374 8745 6461 3733 5450 UE:  21.9 (0-9 yrs);  
25.0 (>9 yrs)
155480 29
Poliomyelitis 0 0 0 0 0 - 0 0
Rabies 0 1 0 0 0 UE: 1 0.2 0.2
Rubella 1 2 7 0 1 UE: 
Uniform(11.11,14.93)
29 0.002
Tetanus n.a. n.a. 1 1 6 UE: Uniform(1.0,1.41) 3 0.3
Foodborne diseases
Campylobacteriosis (c,e) 6731 6431 7256 8294 8547 See Havelaar et al. (13, 
20)
95420 39
Cryptosporidiosis (c,f) 184 184 184 184 184 See Havelaar et al. (13, 
20)
28100 2
Giardiasis (c,g) 2331 2142 1982 1821 1658 See Havelaar et al. (13, 
20)
78960 2
Hepatitis A infection (c) 168 183 176 262 125 See Havelaar et al. (13, 
20)
894 3
Listeriosis (c)
- perinatal 
- acquired
66
6
60
52
1
51
79
3
76
77
4
73
88
9
79
See Havelaar et al. (13, 
20)
72
5
68
5
1
4
Norovirus infection (c) n.a. n.a. n.a. n.a. n.a. See Havelaar et al. (13, 
20)
655100 60
Salmonellosis (c,e) 1968 2576 1921 2291 2029 See Havelaar et al. (13, 
20)
38820 40
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Table 3.2 (continued) Total number of new cases in the years 2007-2011, multiplication factors (MFs) 
chosen to adjust for under-estimation, and the estimated annual number of new cases and deaths (averaged 
over the period 2007-2011 and adjusted for under-estimation), per disease.
Disease Total number of new cases MF(s) chosen 
(see Appendix 2)
Estimated annual 
number 2007-2011
2007 2008 2009 2010 2011 Infections Deaths
Shigellosis (h) 389 438 411 522 577 UE: PERT(1.2,11.6,49.6) 7561 1
Toxoplasmosis (c)
- congenital 
- acquired
n.a. n.a. n.a. n.a. n.a. See Havelaar et al. (13, 
20)
795
371
424
13
13
0
vCreutzfeldt-Jakob 
disease
0 0 1 0 0 UE: 1 0.2 0.2
Infection with STEC O157 
(c)
83 45 57 51 65 See Havelaar et al. (13, 
20)
2128 4
Respiratory diseases
Influenza ** 39028 73455 135170 18390 92887 UA: Uniform(4.12,5.13)
UR: 1
331995 432
Legionellosis 322 337 252 467 312 UA: 1
UR: 
PERT(9.95,11.03,24.14)
4407 176
Q fever 168 1000 2354 504 81 UE: 
PERT(0.75,1.575,3.25) 
(0-14 yrs)
PERT(2.4,5.04,10.4)  
(15+ yrs)
11271 18
Tuberculosis * 999 1013 1158 1068 1003 UA: 1
UR: Uniform(1.08,1.16)
16295 60
UE = under-estimation, UA = under-ascertainment, UR = under-reporting.
Notes: *  Cases with unknown age and/or sex were imputed using the univariate method.
 **  Because the sex distribution of cases was unknown, we applied the sex distribution of the total 
population.
(a)  Reported cases are assumed same for each year; representing the total of cases at centres for sexually-transmitted infections 
 (2010) and cases at sentinel general practitioners (averaged over 2008-2011).
(b)  Estimated annual number of cases also reflects adjustment for reporting delay.
(c)  For these foodborne diseases, a different estimation method was used, see Havelaar et al., 2012 (13, 20).
(d)  MF is a weighted sum derived from the estimated incidence of HCV among HIV-positive and HIV-negative MSM, weighted for the
 proportion of notified cases represented by the two respective groups. Note that the estimated annual incidence is quite uncertain 
(95% CI: 855-1662); this is due to the wide MF distribution specified for HIV-negative MSM, itself attributable to the wide 
uncertainty range in the incidence rate estimated for this group. This MF was only applied to males aged 20-69 years; for all other 
age groups and females, MF was set to 1.
(e)  Corrected for coverage of the sentinel surveillance system: 25% coverage for invasive pneumococcal disease, 52% coverage for
 campylobacteriosis, and 64% coverage for salmonellosis.
(f)  Calculated from the reported incidence rate for 2007; a constant incidence from 2007 onwards was assumed.
(g)  Calculated from a linear regression model fitted to the reported incidence rate between 2001-2007.
(h)  Total notified cases for 2011 includes 161 cases that were not culture-confirmed and perhaps should have not been included; this 
 was due to the sudden popularity of PCR testing and culture-confirmation in 2011-12. Culture-confirmation has been legally 
required since 2013.
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Table 3.3 Estimated annual burden in the period 2007-2011 for new cases of sexually-transmitted infecti-
ons, vaccine-preventable diseases, foodborne diseases, and respiratory diseases in this period: mean (with 
95% uncertainty intervals) YLD/year, YLL/year, DALYs/year, and DALYs/100 cases.
Disease YLD/year YLL/year DALYs/year DALYs/100 cases
Sexually transmitted infections
Chlamydia 3551 
(1470-7327)
0.1 
(0.1-0.2)
3551 
(1470-7328)
2.0 
(0.8-4.0)
Gonorrhoea 1269 
(666-2320)
2.0 
(1.3-3.1)
1271 
(668-2323)
14 
(7-25)
Hepatitis B infection 268 
(267-270)
241 
(212-269)
509 
(480-538)
157 
(148-165)
Hepatitis C infection 2209 
(1536-3026)
65 
(45-95)
2274 
(1600-3085)
749 
(672-834)
HIV infection 3811 
(3461-4175)
3176 
(2889-3476)
6987 
(6374-7622)
618 
(564-675)
Syphilis 13 
(9-17)
14 
(10-18)
26 
(20-35)
0.5 
(0.3-0.6)
Vaccine-preventable diseases
Diphtheria 0 0 0 n.a.
Invasive H. 
 influenzae infection
103 
(93-112)
337 
(316-358)
439 
(415-464)
308 
(292-325)
Invasive 
 meningococcal disease
77 
(64-91)
988 
(823-1159)
1065 
(889-1250)
686 
(638-733)
Invasive 
 pneumoococcal disease
148 
(146-150)
9296 
(8767-9811)
9444 
(8911-9961)
346 
(327-365)
Measles 12 
(11-13)
119 
(91-145)
130 
(103-157)
25 
(20-30)
Mumps 3.4 
(3.1-3.6)
0.3 
(0.2-0.4)
3.7 
(3.4-4.0)
0.5 
(0.5-0.6)
Pertussis 1633 
(1625-1641)
1602 
(1593-1610)
3235 
(3219-3251)
2.1 
(2.1-2.1)
Poliomyelitis 0 0 0 n.a.
Rabies 0.01 
(0.01-0.01)
10 
(10-10)
10 
(10-10)
5081 
(5081-5081)
Rubella 0.04 
(0.03-0.04)
0.10 
(0.08-0.12)
0.14 
(0.12-0.16)
0.5 
(0.4-0.5)
Tetanus 0.07 
(0.07-0.08)
4.3 
(3.9-4.7)
4.4 
(4.0-4.8)
137 
(132-143)
Foodborne diseases
Campylobacteriosis * 2780 
(864-6274)
534 
(333-809)
3314 
(1286-6872)
3.5 
(2.4-7.4)
Cryptosporidiosis * 53 
(30-83)
22 
(0.4-99)
75 
(38-155)
0.3 
(0.1-0.7)
Giardiasis * 121 
(65-206)
29 
(0.7-117)
150 
(78-263)
0.2 
(0.1-0.4)
Hepatitis A infection * 53 
(37-83)
95 
(57-158)
148 
(96-237)
17 
(13-21)
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Table 3.3 (continued) Estimated annual burden in the period 2007-2011 for new cases of sexually-transmit-
ted infections, vaccine-preventable diseases, foodborne diseases, and respiratory diseases in this period: 
mean (with 95% uncertainty intervals) YLD/year, YLL/year, DALYs/year, and DALYs/100 cases.
Disease YLD/year YLL/year DALYs/year DALYs/100 cases
Listeriosis *
- perinatal
- acquired
50 
(29-73)
33 
(17-51)
17 
(12-22)
109 
(109-109)
81 
27 
158 
(137-182)
114 
(98-132)
44 
(39-50)
219 
(195-246)
2482 
(2128-2862)
65 
(59-73)
Norovirus infection * 318 
(209-470)
1329 
(588-2461)
1647 
(900-2783)
0.3 
(0.1-0.4)
Salmonellosis * 913 
(238-2456)
462 
(402-526)
1375 
(671-2877)
3.5 
(2.3-10.9)
Shigellosis 163 
(131-198)
33 
(26-40)
196 
(158-236)
2.6 
(2.5-2.7)
Toxoplasmosis *
- congenital
- acquired
2534 
(1114-4725)
1192 
(485-2449)
1342 
(630-2276)
1059 
(600-1825)
1059 
(681-1906)
0 
3593 
(1715-6601)
2251 
(1088-4322)
1342 
(627-2279)
452 
(383-583)
607 
(450-942)
317 
(317-317)
vCreutzfeldt-Jakob disease 0.2 
(0.1-0.3)
7.0 
(6.8-7.1)
7.2 
(7.1-7.2)
3581 
(3540-3611)
Infection with STEC O157 * 23 
(13-37)
115 
(67-212)
138 
(80-250)
6.5 
(1.5-65)
Respiratory diseases
Influenza 4090 
(3993-4187)
4580 
(4474-4687)
8670 
(8468-8874)
2.6 
(2.6-2.6)
Legionellosis 391 
(351-435)
3892 
(3447-4389)
4283 
(3819-4805)
97 
(90-105)
Q fever 1568 
(1386-1755)
574 
(508-642)
2143 
(1897-2395)
48 
(47-49)
Tuberculosis 126 
(121-130)
2615 
(2117-3138)
2741 
(2241-3264)
233 
(191-278)
* Burden estimated using the methods of Havelaar et al. (13, 20).
estimates with 95% uncertainty intervals are provi-
ded. In the following sections, we present the results 
for these 32 diseases grouped into four mutually 
exclusive disease categories: sexually-transmitted 
infections, vaccine-preventable diseases, foodborne 
diseases, and respiratory diseases.
3.3.1 Sexually-transmitted infections
Figure 3.2 shows the estimated average annual burden 
(in DALYs/year) in the period 2007-2011 for new cases of 
the six STI, with the YLD and YLL components shown 
separately, and uncertainty around the mean DALYs/
year value indicated. The greatest disease burden 
within this disease group was estimated for HIV 
infection (6987 DALYs/year; largely driven by high 
mortality: 115 estimated deaths per year and 3176 YLL/
year; note that HAART was not taken into account), 
followed by chlamydia (3551 DALYs/year), hepatitis C 
infection (2274 DALYs/year), and gonorrhoea (1271 
DALYs/year). Please refer to Table 3.3 for the associated 
95% uncertainty intervals.
The relationship between individual-level burden 
(DALYs/100 cases) and population-level burden 
(DALYs/year) is depicted in Figure 3.6. Syphilis has a 
relatively low burden at both the population and the 
individual levels. The other sexually-transmitted 
infections included have a relatively high populati-
on-level burden, but for chlamydia and gonorrhoea 
the burden at individual level is limited compared 
with HIV, hepatitis B and hepatitis C infection.
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Figure 3.2 Estimated annual burden in the period 2007-2011 for new cases of sexually-transmitted 
infections in this period, with the YLD and YLL components shown separately.
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Note 1: red lines indicate 95% uncertainty intervals.
Note 2: vaccination is available for hepatitis B infection only (in the Netherlands behavioural high-risk groups have been vaccinated 
since 2002, universal childhood vaccination has been introduced in 2011).
3.3.2 Vaccine-preventable diseases
The estimated average annual burden of the 11 
vaccine-preventable diseases for new cases in the 
period 2007-2011 is depicted in Figure 3.3 For 
diphtheria and poliomyelitis, there was zero estima-
ted disease burden because there were no cases 
reported in this period. For mumps, rabies, rubella, 
and tetanus, the disease burden was estimated to be 
very low (≤ 10 DALYs/year). Within this disease 
group, the highest burden was estimated for 
invasive pneumococcal disease (9444 DALYs/year; 
reflecting the large impact of mortality: 410 estima-
ted deaths per year and 9296 YLL/year), followed by 
pertussis (3235 DALYs/year), and invasive meningo-
coccal disease (1065 DALYs/year). The burden of 
pertussis and invasive meningococcal disease was 
localised in children; 48% and 72% of the total DALYs 
for these two diseases were in those aged <15 years.
Of the four vaccine-preventable diseases with the 
lowest estimated burden at the population level 
(rubella, mumps, rabies and tetanus), the burden at 
the individual level for the former two diseases is 
low in comparison to the latter two diseases (Figure 
3.7). Note that in this period there were no reported 
cases of congenital rubella syndrome (CRS), which has 
a high individual level burden. Among the vaccine-
preventable diseases with a high estimated disease 
burden at the population level, the individual-level 
burden is also quite high (with the exception of 
pertussis).
3.3.3 Foodborne diseases
Figure 3.4 shows the estimated average annual 
burden in the period 2007-2011 for new cases of the 11 
foodborne diseases considered. The greatest burden 
within this disease group was estimated for toxoplas-
mosis (3593 DALYs/year), campylobacteriosis (3314 
DALYs/year), norovirus infection (1647 DALYs/year), 
and salmonellosis (1375 DALYs/year). For most 
foodborne diseases, the YLL component is relatively 
small.
The relationship between estimated burden at the 
individual level and the population-level burden is 
shown in Figure 3.8. For most foodborne diseases, 
the disease burden at the individual level is low. 
Among the diseases with a high burden at the 
individual level (i.e., variant Creutzfeldt-Jakob 
disease, toxoplasmosis, and listeriosis), the disease 
burden at the population level is comparatively 
limited (with the exception of toxoplasmosis).
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Figure 3.3 Estimated annual burden in the period 2007-2011 for new cases of vaccine-preventable 
diseases in this period, with the YLD and YLL components shown separately.
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Note 1: red lines indicate 95% uncertainty intervals.
Note 2: for the three invasive diseases there was only a vaccine available against certain serotypes in the period 2007-2011:  
Haemophilus influenzae serotype b (Hib), meningococcal C and pneumococcal serotype 4, 6B, 9V, 14, 18C, 19F, 23F.
3.3.4 Respiratory diseases
The estimated average annual disease burden in the 
period 2007-2011 for new cases of the four respira-
tory diseases is provided in Figure 3.5. Within this 
disease group, the greatest disease burden was 
estimated for influenza (8670 DALYs/year) and 
legionellosis (4283 DALYs/year). This was due to a 
high mortality for both diseases (432 (4580 DALYs/
year) and 176 (3892 DALYs/year) estimated deaths 
per year, respectively). Mortality and YLL from 
influenza were disproportionally high in the elderly, 
with 23% of the total DALYs in those aged 75+ years. 
In contrast, 69% of the total burden of legionellosis 
was seen in the age group 45-69 years. 
For all RD, the disease burden at the population level 
is considerably larger than that at the individual level 
(Figure 3.9); the individual-level burden for influenza 
in particular is relatively small (2.6 DALYs/100 cases).
3.4 Discussion
3.4.1 General discussion
This study is the first extensive investigation into the 
burden of infectious diseases in the Netherlands. We 
have compiled disease burden estimates for 32 
diverse infectious diseases - using a common 
pathogen- and incidence-based approach - in a 
single report. For foodborne diseases, there is a long 
history of disease burden estimation (13). A diverse 
selection of infectious diseases, including several 
investigated here, were included in a previous 
comprehensive Dutch burden of disease study, but a 
different methodology was used (22, 23). Preliminary 
estimates for a number of the diseases have already 
been presented in a previous issue of the State of 
Infectious Diseases in the Netherlands, in 2010 (12). 
However, these preliminary estimates are not 
comparable with the current estimates, because the 
parameters of most disease models have been 
modified since then. We note that comparability will 
also be an issue for future burden estimates, as
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Figure 3.4 Estimated annual burden in the period 2007-2011 for new cases of foodborne diseases in this 
period, with the YLD and YLL components shown separately.
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Note 1: red lines indicate 95% uncertainty intervals.
Note 2: vaccination is available for hepatitis A infection only (only advised for certain groups in the Netherlands).
improvements to the methodology are a natural 
consequence of scientific progress, and disease 
models are continually being refined.
The estimated disease burden varied greatly across a 
set of pathogens that possess very different patterns 
of incidence and associated health outcomes. At the 
population level, invasive pneumococcal disease 
accounted for the highest annual burden, with an 
estimated 9444 DALYs/year, followed by influenza, at 
8670 DALYs/year. At the individual level (i.e., as 
captured by the number of DALYs per 100 cases 
measure), rabies and variant Creutzfeldt-Jakob 
diseases had the highest burden, with 5081 and 3581 
DALYs/100 cases respectively (but these diseases, 
together with diphtheria and poliomyelitis, occur 
with a very low incidence).
3.4.2 Discussion by disease group
3.4.2.1  Sexually-transmitted infections
For most STI, the estimated disease burden was 
relatively high, which is attributable to either a 
severe natural history (e.g., HIV, hepatitis B, and 
hepatitis C infection), or a high incidence (e.g., 
chlamydia and gonorrhoea). Because most sexually-
transmitted infections are not notifiable, it was a 
challenge to get good estimates of the national 
incidence. Furthermore, most surveillance systems 
for sexually-transmitted infections focus on specific 
high-risk groups visiting clinics for sexually-trans-
mitted infections. Therefore, estimating the degree 
of under-ascertainment for these diseases is also 
extremely difficult.
The current disease burden estimates only reflect 
the burden of new cases that occurred in the period 
2007-2011. This means that, for diseases with 
chronic manifestations (e.g., hepatitis B, hepatitis C, 
and HIV infection), our estimation method did not 
take into account chronic cases that had been 
infected prior to this period. The relatively low 
disease burden of hepatitis B infection in the 
Netherlands is likely due to vaccination of high-risk 
groups, for example men who have sex with men 
(MSM), drug users, commercial sex workers, and 
heterosexuals who change partners frequently. This 
selective vaccination programme, begun in 2002, 
has been shown to reduce the incidence of acute 
hepatitis B infection, chiefly by preventing hepatitis 
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Figure 3.5 Estimated annual burden in the period 2007-2011 for new cases of respiratory diseases in this 
period, with the YLD and YLL components shown separately.
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Note 1: red lines indicate 95% uncertainty intervals.
Note 2: vaccination is available for influenza and tuberculosis (in the Netherlands influenza vaccination is offered to high-risk groups 
and people aged 60 or older; the BCG (Bacillus Calmette-Guérin) vaccine against tuberculosis is only advised for certain groups).
B infections in MSM (24). Additionally, children at 
high risk (i.e., children with at least one parent born 
in a hepatitis B endemic country, and children whose 
mother tested positive for HBsAg) have been 
vaccinated against hepatitis B within the National 
Immunisation Programme (NIP) since 2003. 
Universal hepatitis B vaccination was introduced to 
the Dutch NIP in 2011; this is expected to affect 
future disease burden estimates. An explanation for 
the relatively high YLL estimated for hepatitis B as 
compared with hepatitis C infection is the difference 
in the age distributions of notified cases: hepatitis C 
cases tend to be somewhat older and therefore have 
a lower risk of progressing to severe sequelae before 
the end of their natural lifetime.
For HIV infection we used the estimated proportion 
of undiagnosed HIV infections (25) as a proxy for the 
proportion of asymptomatic HIV infections. This may 
have resulted in over-estimation of the number of 
symptomatic infections, and therefore the disease 
burden, because the undiagnosed proportion is 
based on living infected persons only. Symptomatic 
persons were more likely to die in the pre-HAART era 
compared with the post-HAART eras. We note that 
burden was based on a natural history model 
excluding the effects of HAART; a much reduced 
burden would be expected if the positive impact of 
treatment on mortality is taken into account. 
Nevertheless, for a severe disease such as HIV 
infection - with almost two thousand estimated new 
cases annually - inclusion in the list of notifiable 
diseases should perhaps be reconsidered. For HIV, 
and especially hepatitis C infection, treatment 
options have recently changed, or will change in the 
near future, which will lead to improved prognosis 
and a consequent reduction in burden.
The estimated relatively high disease burden of 
chlamydia is striking. Chlamydia was the most 
frequently diagnosed bacterial sexually-transmitted 
infection in 2012, and the positivity rate has incre-
ased in recent years, especially in the younger age 
groups (26). Unfortunately, the Chlamydia Screening 
Implementation (CSI), a large scale trial offering 
annual screening to more than 300,000 young 
people in Amsterdam, Rotterdam and South-
Limburg showed that population based chlamydia 
screening in the Netherlands is unlikely to be cost 
effective (27).
3.4.2.2  Vaccine-preventable diseases
Universal vaccination in the Netherlands against 
diphtheria, pertussis, tetanus and poliomyelitis 
began in the 1950s with the introduction of the NIP, 
and was followed by vaccination against rubella (in
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Figure 3.6 Ranking of sexually-transmitted infections by estimated burden at population (DALYs/year) and 
individual level (DALYs/100 cases) in the period 2007-2011.  
The area of each bubble is proportional to the average number of estimated annual cases.
10,000
1,000
100
10
1
Syphilis
Chlamydia
Gonorrhoea
Hepatitis B infection
Hepatitis C infection HIV infection
0.1
0.01
0.1 1 10 100 1,000 10,000 100,000
D
A
LY
s/
10
0 
ca
se
s
DALYs/year
Note 1: both axes are on a logarithmic scale.
Note 2: vaccination is available for hepatitis B infection only (in the Netherlands behavioural high-risk groups have been vaccinated 
since 2002, universal childhood vaccination has been introduced in 2011).
1974), measles (1976), mumps (1987), and 
Haemophilus influenzae type b (1993). More recently, 
the NIP was expanded with vaccination against 
meningococcal C disease (2002), pneumococcal 
disease (2006), human papilloma virus (2009), and 
hepatitis B infection (2011). The estimated disease 
burden for most of the vaccine-preventable diseases 
is relatively low, testimony to the effectiveness of 
the NIP (28-30) which has achieved a high coverage 
(31). It is vital to maintain this attained level of 
coverage in the future to prevent resurgence of 
those vaccine-preventable diseases that are cur-
rently under control. The current burden estimates 
for vaccine-preventable diseases are consistent with 
the general perception that pertussis is not yet under 
control, and that vaccination against invasive 
bacterial disease (H. influenzae, meningococcal, and in 
particular pneumococcal infection) only protects 
against certain serotypes. 
In 2012, which was an epidemic year for pertussis, 
the estimated disease burden was more than twice 
as high (6842 DALYs and 63 deaths) than the estima-
ted annual burden in the period 2007-2011 (3235 
DALYs/year and 29 deaths). Although the number of 
officially reported pertussis deaths (2 in the period 
2007-2011 (32)) might be under-estimated to some 
extent, especially among older people, an annual 
average of 29 pertussis deaths during 2007-2011 and 
63 deaths during 2012 is probably unrealistic for the 
Dutch situation. In comparison: in England 18 of 46 
estimated pertussis deaths were officially reported 
and 9 annual pertussis deaths were estimated in 
total (33). Therefore, it is likely that we have some-
what over-estimated the disease burden of 
pertussis.
As mentioned before, current vaccines do not cover 
all H. influenzae, meningococcal and pneumococcal 
serotypes; however, our results illustrate the 
effectiveness of the NIP because the vaccine-preven-
table serotypes are under control. In the period 
2007-2011, 30% of the burden of invasive H. influenzae 
disease was caused by serotype b (Hib), only 4% of 
the burden of invasive meningococcal disease was 
due to Men C (86% was caused by Men B, for which 
vaccination is not included in the NIP), and 25% of 
the burden of invasive pneumococcal disease was 
caused by a serotype covered by the 7-valent 
pneumococcal vaccine (PCV7) that was used until 
2011. For invasive pneumococcal disease, for which 
vaccination was introduced in the NIP in 2006, this 
proportion decreased from 40% in 2007 to 15% in 
2011. However, although pneumococcal conjugate 
vaccination decreases the occurrence of vaccine-
type invasive pneumococcal disease, non-vaccine 
type invasive pneumococcal disease may increase 
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Figure 3.7 Ranking of vaccine-preventable diseases by estimated burden at population (DALYs/year) and 
individual level (DALYs/100 cases) in the period 2007-2011; diphtheria and poliomyelitis could not be 
included because there were no cases reported in this period. 
The area of each bubble is proportional to the average number of estimated annual cases (50 cases were 
added to each bubble for visibility reasons).
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Note 1: both axes are on a logarithmic scale.
Note 2: for the three invasive diseases there was only a vaccine available against certain serotypes in the period 2007-2011: 
Haemophilus influenzae serotype b (Hib), meningococcal C and pneumococcal serotype 4, 6B, 9V, 14, 18C, 19F, 23F.
due to serotype replacement, thereby reducing the 
overall benefit of vaccination (34). 
Invasive pneumococcal disease occurs more fre-
quently among the elderly. Due to the ageing of the 
population - it is predicted that more than a quarter 
of the Dutch population will be aged 65 or over in 
2060 (35) - the disease burden for (invasive) pneu-
mococcal disease is expected to increase in the 
coming years. Vaccination of the elderly against 
pneumococcal disease might mitigate this increase. 
A randomised placebo-controlled trial with approxi-
mately 85,000 participants (CAPITA study) showed 
that PCV13 significantly decreased vaccine-type 
community-acquired pneumonia (CAP) by 46% in 
adults of 65 years or older, and vaccine-type invasive 
pneumococcal disease was significantly reduced by 
75% (36). The actual disease burden for pneumococ-
cal disease is even higher than presented, because 
we computed the burden for the invasive form of 
pneumococcal disease only; the burden of otitis 
media and pneumonia attributable to non-invasive 
pneumococcal infection was not included. Non-
invasive forms of H. influenzae and meningococcal 
infection were also excluded, meaning that compari-
son of the disease burden with other vaccine-pre-
ventable diseases or with infections from other 
disease groups should take this restriction to 
invasive forms into account. Mortality, and thus 
burden, associated with invasive pneumococcal 
disease might have been over-estimated, because 
Dutch data indicates a mortality risk of 12% (34), 
whereas the mortality risk in the disease model was 
set to 10-20%.
For the vaccine-preventable diseases the disease 
burden per year can fluctuate enormously due to 
outbreaks that occur mainly among members of 
orthodox religious communities, who do not 
participate in vaccination programmes (37-40). The 
estimated disease burden due to measles in the 
epidemic year 2013 was, at 9319 DALYs, 139 times 
higher than the annual burden in the inter-epidemic 
period 2001-2012 (67 DALYs/year). The total estima-
ted disease burden for the poliomyelitis outbreak in 
1992/1993 was 442 DALYs (71 reported cases), 
whereas there were no cases and thus no burden in 
the period 2007-2011. The rubella outbreak in 
2004/2005 had a total estimated disease burden of 
8449 DALYs (415 reported cases), compared with <1 
DALY/year in the period 2007-2011; 99.7% of this 
estimated burden could be attributed to CRS. 
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Figure 3.8 Ranking of foodborne diseases by estimated burden at population (DALYs/year) and individual 
level (DALYs/100 cases) in the period 2007-2011. 
The area of each bubble is proportional to the average number of estimated annual cases (200 cases were 
added to each bubble for visibility reasons).
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Note 2: vaccination is available for hepatitis A infection only (only advised for certain groups in the Netherlands).
Prevention of CRS was the principal motivation for 
introducing rubella vaccination. For mumps, the 
estimated disease burden was quite low despite the 
relatively high number of reported cases in the 
period 2007-2011. Even in the epidemic year 2011, 
the estimated disease burden for mumps remained 
low (6 DALYs), due to the fact that the risk of severe 
disease and mortality is relatively low.
3.4.2.3  Foodborne diseases
Of the foodborne diseases, the highest annual 
burden within the period 2007–2011 was estimated 
for toxoplasmosis, campylobacteriosis, norovirus 
infection, and salmonellosis (3593, 3314, 1647, and 
1375 DALYs/year, respectively). The observed high 
population-level burden (as measured by DALYs/
year) of the aforementioned four diseases is mainly 
driven by the large number of persons infected. The 
burden estimates for these four diseases, although 
based on the average incidence over a 5-year period, 
are comparable to previously published estimates 
for the year 2009 only: 3620, 3250, 1480, and 1270 
DALYs for toxoplasmosis, campylobacteriosis, 
norovirus infection, and salmonellosis respectively 
(13). The mean estimated individual-level burden for 
foodborne diseases other than variant Creutzfeldt-
Jakob disease, toxoplasmosis, and listeriosis is very 
low (≤17 DALYs/100 cases).
In the burden estimation approach developed by 
Havelaar et al. (13) (which we applied to all food-
borne diseases except variant Creutzfeldt-Jakob 
disease and shigellosis), transition probabilities for 
the severity of disease were integral to the burden 
calculation for several foodborne diseases; for 
others, separate incidence estimates were made for 
cases in the general population, cases visiting their 
general practitioner, and hospitalised patients. The 
latter method makes use of available national cohort 
studies for a number of health outcomes (incidence 
derived from population-wide studies, general 
practitioner visits, hospital admissions), which are 
attributed to different pathogens through laboratory 
examination of faecal specimens. The two approa-
ches are equivalent if the transition probabilities are 
derived from the same national data sources. 
3.4.2.4  Respiratory diseases
The estimated disease burden for most of the 
respiratory diseases is relatively high, reflecting 
simultaneously the large impact of mortality and the 
large number of incident cases (e.g., influenza). 
Despite recommended vaccination against influenza 
for high-risk groups and people aged 60 or older, this 
disease is associated with significant disease burden.
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Figure 3.9 Ranking of respiratory diseases by estimated burden at population (DALYs/year) and individual 
level (DALYs/100 cases) in the period 2007-2011. 
The area of each bubble is proportional to the average number of estimated annual cases.
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Note 1: both axes are on a logarithmic scale.
Note 2: vaccination is available for influenza and tuberculosis (in the Netherlands influenza vaccination is offered to high-risk groups 
and people aged 60 or older; the BCG (Bacillus Calmette-Guérin) vaccine against tuberculosis is only advised for certain groups).
As for many vaccine-preventable diseases, incidence 
and thus the disease burden of influenza and Q fever 
can fluctuate enormously per year. The burden of Q 
fever in 2009 (the year with the most incident cases 
due to an outbreak that started in 2007) was 
estimated at 6162 DALYs; this can be compared with 
the estimated annual burden of 2143 DALYs/year in 
the period 2007-2011. For influenza, 2009 (the year 
of the H1N1 pandemic) was also the year with the 
most reported cases within this period. The estima-
ted disease burden for 2009 was almost twice as 
high (16,378 DALYs) as the estimated average annual 
burden for the period 2007-2011 (8670 DALYs/year). 
Note that the H1N1 pandemic year incidence was 
included when calculating the annual average 
incidence for the period 2007-2011.
The estimated disease burden for legionellosis is 
considerable; this could be due to several factors. 
Firstly, the large legionellosis burden may be 
attributable to over-estimated incidence, due to the 
relatively high multiplication factor derived from a 
combination of Dutch data and a German study on 
community-acquired and hospitalised pneumonia 
patients (41). The proportion of legionellosis among 
pneumonia cases reported in the literature can vary 
substantially (41-43), and because pneumonia occurs 
frequently in the population, the proportion assu-
med can have a significant effect on the estimated 
incidence of legionellosis. Furthermore, legionellosis 
often has a more severe course than other respira-
tory diseases (e.g., Q fever), and is therefore likely to 
be notified earlier. 
Secondly, the Dutch surveillance system is conside-
red to be of high quality (44, 45), and the number of 
reported cases of legionellosis in the Netherlands is 
relatively high compared with other countries (46). 
Routine use of the Legionella pneumophila urinary 
antigen test has become standard of care in patients 
with severe CAP in many Dutch hospitals (47).
Thirdly, in the period 2007-2011, 40% of the reported 
legionellosis cases (range 32% in 2010 to 46% in 
2007) were travel-related and thus were likely to 
have been acquired abroad. In this period, 43% of 
the estimated disease burden comprised travel-
related legionellosis, which cannot be prevented 
through the implementation of national control 
measures. However, the Netherlands actively 
participates in the European Legionnaires‘ Disease 
Surveillance Network (ELDSNet), which aims to 
prevent and control such travel-associated cases. 
The increase of legionellosis in 2010, the year with 
the lowest proportion (32%) of travel-related 
legionellosis cases within our study period, may have 
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been related to weather conditions (i.e., the unusu-
ally hot summer of 2010, which was followed by 
extensive rainfall) or to environmental factors (46, 
48, 49). This exceptional year 2010 had a marked 
effect on the annual disease burden estimate; the 
burden in 2010 was 5863 DALYs compared with 4283 
DALYs/year for the total period 2007-2011.
There are several limitations to the estimated burden 
of tuberculosis. Firstly, migration patterns have 
considerable influence on tuberculosis incidence. In 
recent years, the proportion of patients with extra-
pulmonary tuberculosis (which can differ in clinical 
severity from pulmonary tuberculosis) has increased 
(50), and is notably higher than in other European 
countries (51). This is due to an increased number of 
imported cases among asylum seekers originating 
from Somalia (50). Such recent changes in clinical 
severity are not captured by the disability weights 
used in the current tuberculosis disease model. 
Secondly, we note a risk of double counting of active 
tuberculosis cases. The number of active tuberculosis 
cases that develop from latent infection is deter-
mined by the disease model, by first back-calculating 
the total number of infections from the number of 
reported cases. However, reported cases actually 
represent a mixture of active tuberculosis cases 
following both primary and latent infection, and 
therefore some active tuberculosis cases following 
latent infection may effectively be ‘counted twice’. 
Finally, the transition probability by which patients 
progress to active tuberculosis following primary 
infection (specified as the range 5-10%) is expected 
to be lower for the Netherlands compared with other 
countries due to the practice of screening and 
preventive treatment of latently infected tuberculosis 
contacts and of other high risk groups. Through 
preventive treatment, the risk of developing active 
tuberculosis can be reduced by 60-90% (52).
3.4.3 General limitations
Several disease-specific limitations have already 
been mentioned in the disease group-specific 
sections above. One important additional remark is 
that we have set disease model parameters in 
collaboration with experts to ensure the plausibility 
of the estimated disease burden. This may have 
introduced bias, because diseases for which prelimi-
nary burden calculations were high received more 
attention and provoked more discussion regarding 
model parameters compared with diseases with a 
low estimated burden. Researchers conducting 
disease burden studies in the future are therefore 
advised to strengthen consistency checking among 
disease models.
Secondly, burden estimates are limited by the 
accuracy and comprehensiveness of the pathogen 
outcome trees specified. By linking all health 
consequences causally to the initial infectious event 
(i.e., acute infection), the total estimated health 
burden associated with the pathogen is dependent 
on the correctness of the model. On the one hand, if 
the outcome tree omits a relevant health outcome, 
or the transitional probability of developing a certain 
sequela is too low, then the disease burden would be 
under-estimated. On the other hand, if for some 
health outcomes the specified transition probabili-
ties and/or disability weights are too high, the 
disease burden could be over-estimated. Model 
parameters are sometimes very uncertain and can 
change over time, thus continuous updating of the 
disease models will be necessary. In addition, most 
parameters (i.e., case-fatality rates, transition 
probabilities of progressing to severe sequelae) were 
derived from studies among reported cases, and so 
applying the same parameters also to non-reported 
cases may not always be correct.
For almost all of the diseases investigated, adjust-
ment for under-ascertainment/reporting of notified 
cases was carried out via age- and sex-independent 
multiplication factors, because there was insufficient 
data to specify stratified multiplication factors. As a 
consequence, sex- and/or age-groups with relatively 
more notified severe cases may be over-represen-
ted, and groups with fewer notified severe cases 
may be under-represented (8). Such bias would have 
greater consequences for those diseases with long 
natural histories. Furthermore, multiplication factors 
specific to the Dutch situation were not always 
available, and were therefore necessarily based on 
international studies. In addition, multiplication 
factors may have been derived from very specific 
situations (e.g., during an outbreak year), and may 
not be applicable to the period 2007-2011.
Fourthly, co-morbidity with chronic disease or 
co-infection with other pathogens was not conside-
red. Various methods for adjusting disability weights 
to capture the severity of simultaneous health 
outcomes, and for adjustment of YLL in the case of 
fatal comorbidity have been explored, but have not 
yet reached a satisfactory level of development to 
permit straightforward incorporation in the current 
methodology. 
Variability in annual incidence over time was not 
incorporated, since we calculated the mean inciden-
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ce over the period 2007-2011. Averaging incidence 
across years does not affect the uncertainty regar-
ding the number of incident cases – and hence the 
disease burden – for an ‘average’ year; however, it 
does conceal potentially interesting variation, such 
as outbreaks. For several diseases with periodic 
variation in incidence (e.g., measles, pertussis), we 
have discussed the differences in estimated burden 
between outbreak years and other years (see section 
3.4.2.2 for vaccine-preventable diseases and section 
3.4.2.4 for respiratory diseases).
Finally, the current national disease burden estima-
tes were derived under the ‘steady-state’ assump-
tion; i.e., both the transmission and pathogenicity of 
infections and the size and age-structure of the 
susceptible population were considered static. 
Demographic change, due to population ageing and 
changing migration patterns, diminishing natural 
immunity to certain infectious agents, and new 
interventions would be expected to influence the 
projected future disease burden of most, if not all, 
pathogens (53, 54). Therefore, caution must be 
exercised when extrapolating the estimated burden 
derived from the average number of cases over the 
recent period 2007-2011 to future years.
3.5 Conclusions
This report presents the estimated national disease 
burden for 32 diseases based on the estimated 
annual incidence in the period 2007-2011. The 
estimates depend on the parameters and assumpti-
ons inherent in the disease models, and also on the 
incidence in this specific time frame. Therefore, the 
results represent a first attempt to assess the burden 
of infectious diseases in the Netherlands. It is 
important to develop the disease models further and 
to describe trends in disease burden over time; the 
latter may be a more relevant research goal for some 
investigators than the comparison of diseases with 
each other, as even a standardised burden estimate 
may not capture all the essential information for 
assessing public health impact. The current approach 
to burden estimation may be useful for other 
diseases within the four disease groups considered 
in this report (e.g., human papilloma virus infection, 
infection with Helicobacter pylori), and for other 
disease groups, such as vector-borne diseases (e.g., 
Lyme disease (55)).
Disease burden methodology provides a new 
perspective on infectious disease surveillance data; it 
avoids the devotion of excessive attention to rare 
infections with dramatic outcomes and the neglect 
of common disorders. In general, the disease burden 
also reflects the balance between threats and the 
effectiveness of preventive strategies, such as 
vaccination. A low estimated burden for those 
diseases included in the NIP stresses the need for the 
continued support of these strategies, whereas a 
high burden for diseases covered by the NIP sug-
gests that additional preventive measures may be 
needed. For prioritising interventions and preventive 
measures, estimates of trends in disease burden are 
undoubtedly informative and may reflect the overall 
impact of control efforts. Together with other factors 
such as the availability of preventive strategies, 
costs, and public perception, they can be useful in 
defining public health policy.
3.6 Call for feedback
As this report represents the first comprehensive 
attempt to assess the burden of infectious diseases 
in the Netherlands, we very much welcome input to 
guide further development of the methodology. 
Please send your suggestions regarding model 
parameters, assumptions, and any other remarks to 
Paul Bijkerk (paul.bijkerk@rivm.nl).
Online appendix
See separate file ‘appendix150205001.pdf.
www.rivm.nl/bibliotheek/rapporten/appen-
dix150205001.pdf
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3.8 Appendix 1: surveillance data
General surveillance
Notification of infectious diseases started in the 
Netherlands in 1865. These notification data, 
registered nowadays in OSIRIS, are an important 
source of information on the occurrence of infecti-
ous diseases in the Netherlands. In December 2008, 
a new law (“Wet Publieke Gezondheid”) was passed, 
which meant that physicians, laboratories and heads 
of institutions are required to report 42 notifiable 
infectious diseases to the Public Health Services (see 
Table A.1 below) (56). However, for several diseases 
there is under-ascertainment, under-reporting and 
delay in reporting (57). Because of this under-esti-
mation, it is important to consider the use of 
multiplication factors in burden of disease calculati-
ons. Note that several diseases (e.g., mumps) only 
became notifiable at the end of 2008, but our 
burden calculations were carried out for the period 
2007-2011.
Disease-specific surveillance
Chlamydia, gonorrhoea, syphilis: national surveil-
lance at clinics for sexually-transmitted infections 
(STI) and STI surveillance in general practice
The national STI surveillance system is organised 
into eight regions. In each region there is one STI 
clinic responsible for the coordination of STI 
surveillance. A total of 26 STI clinics provide low-
threshold STI/HIV testing and care, free of charge, 
targeted at high-risk groups. Currently, people who 
satisfy one or more of the following criteria are 
considered to be at high risk of STI acquisition: (1) 
report STI-related symptoms; (2) notified or referred 
for STI testing; (3) are aged below 25 years; (4) MSM; 
(5) are involved in commercial sex work; (6) originate 
from an HIV/STI endemic area; (7) report three or 
more sexual partners in the previous six months; 
and (8) report a partner from a high-risk group. 
Attendees are mandatorily tested for chlamydia, 
gonorrhoea and syphilis and there is an opt-out 
policy for HIV testing. All consultations and corres-
ponding diagnoses are reported online to RIVM for 
surveillance purposes. This process is facilitated by a 
web-based application (SOAP) (26).
Data from general practitioners, who perform the 
bulk of STI consultations, are extrapolated from the 
Netherlands Information Network of General 
Practice (LINH). This sentinel surveillance network 
covers approximately 2.5% of the total Dutch 
population. Ailments and illnesses are recorded 
using the International Classification of Primary Care 
(ICPC) (26).
The number of cases with congenital syphilis was 
based on immunoglobulin M (IgM) diagnostics 
offered by RIVM for neonates and young infants (< 1 
year) who are suspected of being infected with 
congenital syphilis (26).
HIV infection: national registration of patients at 
HIV treatment centres
HIV-infected individuals are registered at 26 recogni-
sed HIV treatment centres and are entered in an 
anonymous HIV/AIDS reporting system for patients 
entering care. These data are collected by Stichting 
HIV Monitoring (the Dutch HIV monitoring founda-
tion) (26).
Invasive H. influenzae disease and invasive pneu-
mococcal disease: Netherlands Reference 
Laboratory for Bacterial Meningitis (NRBM)
The Netherlands Reference Laboratory for Bacterial 
Meningitis (NRBM) is a collaboration between RIVM 
and the Academic Medical Centre of Amsterdam 
(AMC). All microbiological laboratories throughout 
the Netherlands send, on a voluntary basis, H. 
Influenzae isolates from blood and cerebrospinal fluid 
(CSF) to the NRBM for further typing. Nine sentinel 
laboratories throughout the country, covering 
approximately 25% of the Dutch population, are 
asked to send all S. pneumoniae isolates from blood 
and CSF to the NRBM for further typing (58).
Campylobacteriosis, cryptosporidiosis, giardiasis, 
norovirus infection, salmonellosis, toxoplasmosis: 
SENSOR study, sentinel laboratory surveillance, 
and PIENTER study
Data from the SENSOR study (59) were used to 
estimate the incidence of gastroenteritis in the 
Dutch population. Data were updated to reflect the 
period 2007-2011, based on trends in laboratory 
surveillance data. The Dutch laboratory surveillance 
network for gastroenteric pathogens consists of 15 
out of the 16 regional public health laboratories 
serving mainly general practices but also hospitals. 
For each patient, a standardised form is completed 
and sent to RIVM. This surveillance network has a 
52.7% regular coverage and 61.8% effective covera-
ge of the Dutch population. Coverage is based on the 
number of stools screened, which is used as a proxy 
for the number of consulting gastroenteritis cases. 
The coverage of the surveillance network differs by 
pathogen (60). Norovirus infection is not included in 
case-based laboratory surveillance and therefore 
trends in hospitalisation data for viral gastroenteritis
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Table A.1 Diseases that have been notifiable since 2008 (56).
Disease Year of introduction of mandatory notification
Group A*
Smallpox 2004
Polio† 1923
Severe acute respiratory syndrome (SARS) 2003
Group B1*
Avian influenza 2008
Diphtheria† 1872
Plague 1897
Rabies† 1928
Tuberculosis† 1980
Viral haemorrhagic fever 1977
Group B2*
Typhoid fever 1872
Cholera 1872
Hepatitis A† 1950
Hepatitis B† 1950
Hepatitis C† 1998
Invasive group A streptococcal disease 2008
Pertussis† 1975
Measles† 1975
Paratyphus A, B and C 1928
Rubella† 1950
Shigellosis† 1873
Shiga toxin-producing E. coli / enterohemorrhagic 
E. coli infection†
1999
Foodborne infections 1975
Group C*
Anthrax 1975
Mumps† 2008
Botulism 1984
Brucellosis 1928
Yellow fever 1928
Hantavirus infection 2008
Invasive Haemophilus influenzae type b disease† 2008
Invasive pneumococcal disease (for children)† 2008
Legionnaires’ disease† 1987
Leptospirosis 1928
Listeriosis† 2008
Malaria 1940
Meningococcal disease† 1905
MRSA-infection, clusters of 2008
Psittacosis 1940
Q fever† 1975
Tetanus† 2008
Trichinosis 1975
West Nile fever 2008
Creutzfeldt-Jakob disease† 2002
*  Diseases in category A have to be reported directly by telephone following a laboratory-confirmed diagnosis. Diseases in the 
categories B1, B2 and C must be reported within 24 hours or one working day after laboratory confirmation. In each of the latter three 
categories, various intervention measures can be enforced to prevent spreading of the disease.
† Diseases included in this chapter.
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was used. For toxoplasmosis the annual incidence 
was estimated based on seroprevalence data from 
the Pienter study (61).
Listeriosis: enhanced surveillance
From 2005 to December 2008, a voluntary surveil-
lance system for Listeria monocytogenes was in place in 
the Netherlands, in which all public health laborato-
ries were requested to report positive cultures of L. 
monocytogenes to the local public health authorities. 
Laboratories were also asked to continue sending 
isolates from patients with meningitis or sepsis to 
the Dutch Reference Laboratory for Bacterial 
Meningitis (RBM). As part of the surveillance 
procedure, RBM forwards all isolates to RIVM. 
Isolates from patients with other symptoms can be 
sent directly to RIVM for serotyping and PFGE. 
Patients were interviewed by health authorities 
regarding their medical history, illness and exposure 
to possible risk factors in the 30 days before the date 
of illness onset. In December 2008, listeriosis 
became a mandatory notifiable disease. The 
voluntary questionnaire was replaced by a notifica-
tion questionnaire; the voluntary system for the 
submission of isolates remained unchanged.
Influenza: Dutch Sentinel General Practice 
Network
Within the Sentinel General Practice Network of the 
Netherlands Institute for Health Services Research 
(NIVEL), general practitioners submit reports on a 
weekly (or annual) basis on the occurrence of 
diseases, events and treatments that are not covered 
by routine registration. The network covers approxi-
mately 0.8% of the total Dutch population, and is 
representative with regard to age, sex, region and 
degree of urbanisation. For influenza-like-illness 
(ILI), the following definition is used: an illness with 
an acute onset (prodromal stage of ≤4 days), fever 
(defined as a rise in rectal temperature to at least 38 
°C), and at least one of the following symptoms: 
cough, rhinitis, sore throat, frontal headache, 
retrosternal pain, and myalgia (62). Swabs from a 
subset of ILI patients are taken for virological 
analysis to determine the true influenza positivity 
rate.
Tuberculosis: Netherlands Tuberculosis Register 
(NTR) 
The Netherlands Tuberculosis Register held by KNCV 
Tuberculosefonds/RIVM contains all registered 
tuberculosis patients who have been treated or 
diagnosed in the Netherlands. The NTR is an 
anonymous, current database in which relevant 
information on the occurrence of tuberculosis in the 
Netherlands and the results of treatment are 
recorded. It involves all forms of tuberculosis; i.e., 
both pulmonary and extrapulmonary tuberculosis 
(50).
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3.9  Appendix 2: rationale for multiplication factors
Table A.2 Rationale for multiplication factors.
Disease MF(s) chosen Explanation
Sexually transmitted infections
Chlamydia UA: 1 
UR: 1.111
We assumed 10% under-reporting because some 
people get tested in other settings (gynaecologist, 
directly at laboratory, self-test?).
Gonorrhoea UE: 2.53 MF is based on absolute numbers from SOAP and 
LINH.
Hepatitis B infection UA: 1.33
UR: Uniform(1.20,1.22)
For under-ascertainment, we assume that 75% of all 
symptomatic cases is reported; this is based on 
England and Wales data from 1992-1996 (63). For 
under-reporting, the lower bound was derived from a 
1996 audit, and the upper bound was taken from 
Swaan et al.’s (unpub.) study of reporting 
completeness (weighted mean of 83.1%) by 13 Zuid-
Holland laboratories, 2005-2010.
Hepatitis C infection UE: Uniform(1, 5.12)*29/30 
+ PERT(0, 47, 464.4)*1/30
MFs were calculated for MSM only, and it was 
assumed that there is no under-estimation for non-
MSM risk groups. MF is a weighted sum derived from 
the estimated incidences of HCV among HIV-positive 
and HIV-negative MSM, weighted for the proportion 
of notified cases represented by the two respective 
groups. Note that the estimated annual incidence is 
quite uncertain (95% CI: 855-1662); this is due to the 
wide MF distribution specified for HIV-negative MSM, 
itself attributable to the wide uncertainty range in the 
incidence rate estimated for this group. This MF was 
only applied to males aged 20-69 years; for all other 
age groups and females, MF was set to 1.
HIV infection UE: 1 No MF is available to estimate actual incidence from 
diagnoses. Because it takes about two years for the 
HIV diagnosis register to become complete, we 
corrected for reporting delay (to estimate 
completeness as of 2012, the number of diagnoses in 
2011 was multiplied by 11% and the number of 
diagnoses in 2010 was multiplied by 3%). 
Syphilis UE: 4.21 MF based on absolute numbers from SOAP and LINH.
Vaccine-preventable diseases
Diphtheria not applicable not applicable
Invasive  H. 
influenzae infection
UE: Uniform(1.05,1.20) Approximately 83-95% of isolates are sent to the 
Netherlands Reference Laboratory for Bacterial 
Meningitis and this leads to an MF of 1.05 to 1.20.
Invasive 
 meningococcal 
disease
UE: 1.05 Meningococcal disease is a notifiable disease and 
notifications are cross-checked with data of the 
Netherlands Reference Laboratory for Bacterial 
Meningitis. Therefore coverage will be very high, 
around 95%. This leads to an MF of 1.05.
Invasive
pneumococcal 
disease
UE: Uniform(1.05,1.20) Approximately 83-95% of isolates are sent to the 
Netherlands Reference Laboratory for Bacterial 
Meningitis; this leads to an MF of 1.05 to 1.20.
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Table A.2 (continued) Rationale for multiplication factors.
 
Disease MF(s) chosen Explanation
Measles UE: Uniform(11.11,14.93) According to Van Isterdael et al. (2004) (64) 9% of all 
measles cases were reported (MF=11.11). Wallinga et 
al. (2003) (65) estimated that 6.7% of all infections 
were reported (MF=14.93). Both estimates are based 
on the 1999/2000 measles outbreak in the 
Netherlands.
Mumps UA: 1.84
UR: 1
Under-ascertainment MF based on Greenland et al. 
(2010) (66). No data on under-reporting was 
available; we applied MF=1.
Pertussis UE: 21.9 (0-9 yrs);  
          25 (>9 yrs)
MFs are based on Pienter-2 data (67), corrected for 
the proportion symptomatic, separately for children 
0-9 years and for persons >9 years. 
Poliomyelitis UE: 1 Because there were 0 cases in the period 2007-2011, 
this MF was only applied to calculate the disease 
burden of the poliomyelitis outbreak in 1992/1993. 
Because of the severity of the disease, we assumed 
that all cases are identified. 
Rabies UE: 1 Because of the severity of the disease we assumed 
that all cases are identified.
Rubella UE: Uniform(11.11,14.93) No information available. We therefore used the MF 
for measles as a proxy (the clinical picture is probably 
less clear compared with measles, except for 
congenital rubella syndrome). 
Tetanus UE: Uniform(1.0,1.41) Range of 1 to 1.41 was based on expert opinion that 
the MF would be close to 1.0 (set as lower bound), 
and a Danish study suggesting 1.41 (upper bound) 
(68).
Foodborne diseases
Campylobacteriosis,
Cryptosporidiosis,
Giardiasis,
Hepatitis A infection,
Listeriosis,
Norovirus infection,
Salmonellosis,
Toxoplasmosis,
Infection with STEC 
O157
For these foodborne diseases, an estimation method 
developed by Havelaar et al. was used that is specific 
for the Dutch situation (13, 20).
Shigellosis UE: PERT(1.2,11.6,49.6) As a proxy, an MF calculated for salmonellosis (based 
on the proportion of (a) the number of estimated 
salmonellosis cases in 2009 (13) and (b) the mean 
number of reported salmonellosis cases in 2007-
2011) was used.
vCreutzfeldt-Jakob 
disease
UE: 1 No correction due to the 100% fatality of the disease. 
Cases may be missed, especially elderly patients, if 
symptoms are attributed to a different cause.
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Table A.2 (continued) Rationale for multiplication factors.
 
Disease MF(s) chosen Explanation
Respiratory diseases
Influenza UA: Uniform(4.12,5.13)
UR: 1
MF for under-ascertainment is based on the 
estimated proportion of people who go to the general 
practitioner when they have ILI symptoms (source: 
“Grote Griepmeting”). MF ranged from 4.12 to 5.13 in 
the period 2007-2011 (2007: 4.43, 2008: 4.12, 2009: 
4.19, 2010: 5.13 and 2011: 4.42).
Legionellosis UA: 1
UR: 
PERT(9.95,11.03,24.14)
Based on Dutch notification data, the estimated 
number of pneumonia cases in the Netherlands (69, 
70), and the expected proportion with diagnosis 
legionellosis (41-43).
Q fever UE:  PERT(0.75,1.575,3.25) 
(0-14 yrs) 
PERT(2.4,5.04,10.4) 
(15+ yrs)
Van der Hoek et al. (2012) (71) showed that in the 
highest incidence areas of the Netherlands in 2009, 
one notification represented 12.6 infections (95% CI: 
6-26) (either symptomatic or asymptomatic). In the 
international literature, a symptomatic percentage of 
12.5% (0-14 years) and 40% (15 years or older) is 
applied. Therefore, we estimate that one notification 
represents 1.6 (0-14 years) or 5 symptomatic cases 
(15+ years).
Tuberculosis UA: 1
UR: Uniform(1.08,1.16)
Based on Van Hest et al. (2007) (72): 1.08 (record-
linkage study) to 1.16 (capture-recapture analysis).
UE = under-estimation, UA = under-ascertainment, UR = under-reporting.
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Erratum for report 150205001/2014: State of Infectious Diseases in the Netherlands, 2013 
 
In the report “State of Infectious Diseases in the Netherlands, 2013”, the disease burden at 
individual level (DALYs per 100 cases) was not calculated consistently. For most diseases, it was 
calculated as the number of DALYs per 100 infections, but for some exceptions the burden was 
calculated as the number of DALYs per 100 symptomatic cases. These exceptions were hepatitis B 
infection, hepatitis C infection, HIV infection, Q fever, and tuberculosis. Below we present Table 3.3 
and Figures 3.6/3.9 for which the disease burden at individual level was calculated as the number of 
DALYs per 100 infections for all diseases. 
 
Table 3.3 Estimated annual individual level burden in the period 2007-2011 for new cases of 
sexually-transmitted infections, vaccine-preventable diseases, foodborne diseases, and respiratory 
diseases in this period: mean (with 95% uncertainty intervals). 
 
Disease DALYs/ 
100 infections 
Sexually-transmitted infections   
Chlamydia 2.0 (0.8-4.0) 
Gonorrhoea 14 (7-25) 
Hepatitis B infection* 45 (43-48) 
Hepatitis C infection* 184 (130-250) 
HIV infection* 363 (332-396) 
Syphilis 0.5 (0.3-0.6) 
Vaccine-preventable diseases   
Diphtheria n.a.  
I. H. influenzae infection 308 (292-325) 
I. meningococcal disease 686 (638-733) 
I. pneumoococcal disease 346 (327-365) 
Measles 25 (20-30) 
Mumps 0.5 (0.5-0.6) 
Pertussis 2.1 (2.1-2.1) 
Poliomyelitis n.a.  
Rabies 5081 (5081-5081) 
Rubella 0.5 (0.4-0.5) 
Tetanus 137 (132-143) 
Foodborne diseases   
Campylobacteriosis 3.5 (2.4-7.4) 
Cryptosporidiosis 0.3 (0.1-0.7) 
Giardiasis 0.2 (0.1-0.4) 
Hepatitis A infection 17 (13-21) 
Listeriosis 
- perinatal 
- acquired 
219 
2482 
65 
(195-246) 
(2128-2862) 
(59-73) 
Norovirus infection 0.3 (0.1-0.4) 
Salmonellosis 3.5 (2.3-10.9) 
Shigellosis 2.6 (2.5-2.7) 
Toxoplasmosis 
- congenital 
- acquired 
452 
607 
317 
(383-583) 
(450-942) 
(317-317) 
vCreutzfeldt-Jakob disease 3581 (3540-3611) 
Infection with STEC O157 6.5 (1.5-65) 
Respiratory diseases   
Influenza  2.6 (2.6-2.6) 
Legionellosis 97 (90-105) 
Q fever* 19 (17-21) 
Tuberculosis* 17 (14-20) 
* In the original report, the burden at individual level for these diseases was presented per 100 symptomatic 
 cases instead of per 100 infections.  
Figure 3.6 Ranking of sexually-transmitted infections by estimated burden at population 
(DALYs/year) and individual level (DALYs/100 infections) in the period 2007-2011. The area of each 
bubble is proportional to the average number of estimated annual cases. 
 
 
Note 1: both axes are on a logarithmic scale. 
Note 2: vaccination is available for hepatitis B infection only (in the Netherlands behavioural high-risk groups have been 
vaccinated since 2002, universal childhood vaccination has been introduced in 2011). 
 
 
 
Figure 3.9 Ranking of respiratory diseases by estimated burden at population (DALYs/year) and 
individual level (DALYs/100 infections) in the period 2007-2011. The area of each bubble is 
proportional to the average number of estimated annual cases. 
 
 
Note 1: both axes are on a logarithmic scale. 
Note 2: vaccination is available for influenza and tuberculosis (in the Netherlands influenza vaccination is offered to high-risk 
groups and people aged 60 or older; the BCG (Bacillus Calmette-Guérin) vaccine against tuberculosis is only advised for certain 
groups). 
 
 
Voor akkoord, 28-07-2015 
 
 
Dr. M.A.B. van der Sande 
Hoofd Afdeling Epidemiologie en Surveillance van Infectieziekten 
P. Bijkerk et al.
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